0001387131-20-010032.txt : 20201116 0001387131-20-010032.hdr.sgml : 20201116 20201116164739 ACCESSION NUMBER: 0001387131-20-010032 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201116 DATE AS OF CHANGE: 20201116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NANOPHASE TECHNOLOGIES Corp CENTRAL INDEX KEY: 0000883107 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS PRIMARY METAL PRODUCTS [3390] IRS NUMBER: 363687863 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-22333 FILM NUMBER: 201317881 BUSINESS ADDRESS: STREET 1: 1319 MARQUETTE DRIVE CITY: ROMEOVILLE STATE: IL ZIP: 60446 BUSINESS PHONE: 6303231200 MAIL ADDRESS: STREET 1: 1319 MARQUETTE DRIVE CITY: ROMEOVILLE STATE: IL ZIP: 60446 FORMER COMPANY: FORMER CONFORMED NAME: NANOPHASE TECHNOLOGIES CORPORATION DATE OF NAME CHANGE: 19970305 10-Q 1 nanx-10q_093020.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended: September 30, 2020

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the
Securities Exchange Act of 1934

For the transition period from to

Commission File Number: 000-22333

Nanophase Technologies Corporation

(Exact name of registrant as specified in its charter)

Delaware	36-3687863
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

1319 Marquette Drive, Romeoville, Illinois 60446

(Address of principal executive offices, and zip code)

Registrant’s telephone number, including area code: (630) 771-6708

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		NANX		OTCQB

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “accelerated filer”, “large accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☐	Smaller reporting company ☑
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

As of November 16, 2020, there were 38,215,792 shares outstanding of common stock, par value $.01, of the registrant.

NANOPHASE TECHNOLOGIES CORPORATION

QUARTER ENDED SEPTEMBER 30, 2020

INDEX

		Page

PART I - FINANCIAL INFORMATION		1
Item 1. Unaudited Consolidated Condensed Financial Statements		1
Balance Sheets (Unaudited Consolidated Condensed) as of September 30, 2020 and December 31, 2019		1
Statements of Operations (Unaudited Consolidated Condensed) for the three and nine months ended September 30, 2020 and 2019		2
Statements of Stockholders' Equity (Unaudited Consolidated Condensed) for the three and nine months ended September 30, 2020 and 2019		3
Statements of Cash Flows (Unaudited Consolidated Condensed) for the nine months ended September 30, 2020 and 2019		4
Notes to Unaudited Consolidated Condensed Financial Statements		5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		15
Item 3. Quantitative and Qualitative Disclosures About Market Risk		20
Item 4. Controls and Procedures		21

PART II - OTHER INFORMATION		21
Item 1. Legal Proceedings		21
Item 1A. Risk Factors		21
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		21
Item 3. Defaults Upon Senior Securities		21
Item 4. Mine Safety Disclosures		21
Item 5. Other Information		21
Item 6. Exhibits		22

SIGNATURES		23

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

NANOPHASE TECHNOLOGIES CORPORATION

CONSOLIDATED BALANCE SHEETS

(Unaudited Consolidated Condensed)

(in thousands except share and per share data)

	September 30, 2020			December 31, 2019
	(Unaudited)			(Unaudited)
ASSETS

Current assets:
Cash	$	1,134		$	1,194
Trade accounts receivable, less allowance for doubtful accounts of $9 on September 30, 2020 and on December 31, 2019, respectively		2,451			970
Inventories, net		3,584			2,554
Prepaid expenses and other current assets		599			267
Total current assets		7,768			4,985
Equipment and leasehold improvements, net		2,650			2,255
Operating leases, right-of-use		1,917			2,119
Other assets, net		11			13
TOTAL ASSETS	$	12,346		$	9,372

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Line of credit, bank	$	500		$	500
Line of credit, related party		1,541			224
Current portion of long-term debt, related party		500			500
Current portion of finance lease obligations		186			218
Current portion of operating lease obligations		411			357
Accounts payable		1,668			1,748
Current portion of deferred revenue		309			482
Accrued expenses		647			380
Total current liabilities		5,762			4,409

Long-term portion of finance lease obligations		148			288
Long-term portion of operating lease obligations		1,766			2,035
Long-term convertible loan, related party		1,030			830
PPP Loan SBA		952			—
Long-term portion of deferred revenue		—			93
Asset retirement obligations		212			206
Total long-term liabilities		4,108			3,452

Contingent liabilities:		—			—

Stockholders' equity:
Preferred stock, $.01 par value, 24,088 shares authorized and no shares issued and outstanding		—			—
Common stock, $.01 par value, 55,000,000 shares authorized; 38,215,069 and 38,136,792 shares issued and outstanding on September 30, 2020 and December 31, 2019, respectively		382			381
Additional paid-in capital		102,055			101,886
Accumulated deficit		(99,961	)		(100,756	)
Total stockholders' equity		2,476			1,511
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	12,346		$	9,372

See Notes to Consolidated Condensed Financial Statements.

NANOPHASE TECHNOLOGIES CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited Consolidated Condensed)


	Three Months Ended					Nine Months Ended
	September 30,					September 30,
	2020		2019			2020		2019
Revenue:
Product revenue	$	3,827	$	3,043		$	11,929	$	9,797
Other revenue		61		26			333		321
Total revenue		3,888		3,069			12,262		10,118

Operating expense:
Cost of good revenue		2,201		2,506			7,832		7,839
Gross profit		1,687		563			4,430		2,279

Research and development expense		405		488			1,134		1,450
Selling, general and administrative expense		730		890			2,133		2,711
Income/(loss) from operations		552		(815	)		1,163		(1,882	)

Interest expense		122		47			368		140
Income/(loss) before provision for income taxes	$	430	$	(862	)	$	795	$	(2,022	)
Provision for income taxes		—		—			—		—
Net income/(loss)	$	430	$	(862	)	$	795	$	(2,022	)

Net income/(loss) per basic shares	$	0.01	$	(0.02	)	$	0.02	$	(0.06	)
Weighted average number of basic common shares outstanding		38,141,741		38,136,792			38,138,453		36,077,257
Net income/(loss) per diluted share	$	0.01	$	(0.02	)	$	0.02	$	(0.06	)
Weighted average number of diluted common shares outstanding		38,432,741		38,136,792			38,228,453		36,077,257

See Notes to Consolidated Condensed Financial Statements.

NANOPHASE TECHNOLOGIES CORPORATION

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited Consolidated Condensed)

(In thousands except share data)

	Preferred Stock				Common Stock				Additional		Accumulated
Description	Shares		Amount		Shares		Amount		Paid-in-Capital		Deficit			Total
Balance on December 31, 2018		—	$	—		33,911,792	$	339	$	98,795	$	(97,750	)	$	1,384
Stock-based compensation		—		—		—		—		57		—			57
Net loss		—		—		—		—		—		(513	)		(513	)
Balance on March 31, 2019		—	$	—		33,911,792	$	339	$	98,852	$	(98,263	)	$	928
Stock option exercises		—		—		36,000		—		16		—			16
Stock-based compensation		—		—		—		—		58		—			58
Issuance of Common Stock		—		—		4,189,000		42		1,634		—			1,676
Net loss		—		—		—		—		—		(647	)		(647	)
Balance on June 30, 2019		—	$	—		38,136,792	$	381	$	100,560	$	(98,910	)	$	2,031
Stock-based compensation		—		—		—		—		64		—			64
Net loss		—		—		—		—		—		(862	)		(862	)
Balance on September 30, 2019		—	$	—		38,136,792	$	381	$	100,624	$	(99,772	)	$	1,233

Balance on December 31, 2019		—	$	—		38,136,792	$	381	$	101,886	$	(100,756	)	$	1,511
Stock-based compensation		—		—		—		—		52		—			52
Net loss		—		—		—		—		—		(167	)		(167	)
Balance on March 31, 2020		—	$	—		38,136,792	$	381	$	101,938	$	(100,923	)	$	1,396
Stock-based compensation		—		—		—		—		47		—			47
Net income		—		—		—		—		—		532			532
Balance on June 30, 2020		—	$	—		38,136,792	$	381	$	101,985	$	(100,391	)	$	1,975
Stock option exercises		—		—		78,277		1		22		—			23
Stock-based compensation		—		—		—		—		48		—			48
Net income		—		—		—		—		—		430			430
Balance on September 30, 2020		—	$	—		38,215,069	$	382	$	102,055	$	(99,961	)	$	2,476

See Notes to Consolidated Condensed Financial Statements.

NANOPHASE TECHNOLOGIES CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited Consolidated Condensed)

	Nine months ended
	September 30,
	2020			2019
Operating Activities:
Net income (loss)	$	795		$	(2,022	)
Adjustements to reconcile net loss to cash used in operating activities:
Depreciation and amortization		265			234
Loss on disposal of equipment and leasehold improvements		—			16
Share-based compensation		147			179
Amortization of debt discount		200			—

Changes in assets and liabilities related to operations:
Trade accounts receivable		(1,481	)		(544	)
Inventories		(1,030	)		98
Prepaid expenses and other assets		(332	)		(12	)
Accounts payable		(284	)		(632	)
Accrued expenses		267			(19	)
Deferred revenue		(266	)		594
Other long-term assets and liabilities		(13	)		(53	)
Net cash used in operating activities		(1,732	)		(2,161	)

Investing activities:
Acquisition of equipment and leasehold improvements		(448	)		(523	)
Net cash used in investing activities		(448	)		(523	)

Financing activities:
Principal payments on finance leases		(172	)		(162	)
Proceeds from line of credit, bank		1,500			1,000
Payments to the line of credit, bank		(1,500	)		(500	)
Proceeds from the line of credit, related party		10,390			8,166
Payments to the line of credit, related party		(9,073	)		(7,895	)
Proceeds from PPP / SBA Loan		952			—
Proceeds from issuance of common stock		—			1,676
Proceeds from stock option exercises		23			16
Net cash provided by financing activities		2,120			2,301

Increase (decrease) in cash and cash equivalents		(60	)		(383	)
Cash and cash equivalents at beginning of period		1,194			1,345
Cash and cash equivalents at end of period	$	1,134		$	962

Supplemental cash flow information:
Interest paid	$	152		$	126

Supplemental non-cash investing and finacing activities:
Accounts payable incurred for the purchase of equipment and leasehold improvements	$	204		$	18

See Notes to Consolidated Condensed Financial Statements.

NANOPHASE TECHNOLOGIES CORPORATION

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(Unaudited Consolidated Condensed)

(in thousands, except share and per share data or as otherwise noted herein)

(1) Basis of Presentation

The accompanying unaudited consolidated condensed interim financial statements of Nanophase Technologies Corporation (“Nanophase”, “Company”, “we”, “our”, or “us”) reflect all adjustments (consisting of normal recurring adjustments) which, in the opinion of management, are necessary for a fair presentation of our financial position and operating results for the interim periods presented. All statements include the results from both Nanophase and our wholly owned subsidiary, Solésence, LLC (“Solésence®,” or our “Solésence® subsidiary”). Operating results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020.

These financial statements should be read in conjunction with our audited financial statements and notes thereto for the year ended December 31, 2019, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission.

(2) Going Concern / Liquidity

We believe that cash from operations and cash on hand, in addition to unused borrowing capacity, may not be adequate to fund our operating plans through September 30, 2021. We are working to reduce these risks, but some of this is dependent on several things, some of which we have limited control. Our largest customer made up 63% of our 2019 revenue and has seen a significant reduction in orders placed to us in 2020. We have also seen a rapid increase in sales of our Solésence® products, adding working capital pressure in terms of additional inventory and accounts receivable. Both of these issues have limited our flexibility and required us to make cash management a top priority. After April 17, 2020, some of this pressure was mitigated due to our receipt of a $952 loan under the Paycheck Protection Program (the “PPP”), as discussed more fully below. We also have a $500 term loan, and revolving credit facility with a maximum credit limit of $2,750, both described more fully below, with principal due on March 31, 2021. In the event that we are unable to either extend the maturity, or potentially refinance this loan, we may have difficulty funding ongoing operations. Notwithstanding the fact that visibility into the ongoing impact of the various reactions and policies relating to, the Covid-19 pandemic is limited, it is currently management’s belief that we will continue to achieve strong growth in Solésence® sales through 2020. Given these issues, and other commercial realities, we are monitoring the additional working capital demands that this could create as we continue to execute on our Solésence® growth strategy. It is also management’s belief that the Covid-19 pandemic, related governmental reaction, and resulting economic slow-down has, and is expected to continue, to affect certain consumer behaviors and markets has had a negative impact on its Personal Care Ingredients customers during 2020, with a current lack of visibility as to how far this impact may extend in to 2021. Management believes the outlook after the fourth quarter is uncertain, but a continuation of the Covid-19 pandemic and related reactions and policies going forward would be expected to maintain a degree of negative impact on the Company and its businesses. While customer demand over the next several months is currently known, Management believes the negative impacts late in the fourth quarter and, if applicable, thereafter, are not currently quantifiable. The timing of cash flows is critical. If cash generated from operations is not materially consistent with our plans, we believe that we may need to seek additional funding to address working capital demands. The trading volume of our stock has been low enough that we expect it would be difficult to sell enough shares, assuming our shareholders would approve the authorization of additional shares, to generate additional capital via the OTC market. These uncertainties have caused us to be unable to assert that, for the next twelve months, we have enough current cash, guaranteed access to financing to fund operations, or access to cash in the equity markets to continue with our current growth strategy in terms of investment in capital equipment and in operating expenses related to Solésence®.

On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (SARS-CoV-2) to be a global pandemic (COVID-19), which continues to spread throughout the United States and around the world. On April 23, 2020, the Governor of the State of Illinois extended his order that all non-essential businesses cease all activities within the State of Illinois except for certain minimum basic operations through May 30, 2020, and such executive order has been temporarily lifted. Given the uncertain progress toward combatting the SARS-CoV-2 virus, we expect there to be further disruptions in the local, national, and global economies. During these disruptions, we are doing everything we can to allow as many of our employees as possible to shelter-in-place. Relative to any further executive orders in Illinois, management believes that Nanophase Technologies and its Solésence® subsidiary qualify as essential businesses as defined, due to our product offerings supporting healthcare, and critical manufacturing and chemical products within sectors that have been designated as critical infrastructure, the continued operation of which is vital for national public health, economic security, and safety.

The Company believes that its customers and suppliers may have similar disruptions, which may lead to greater reductions in their normal operations as a result of responses to the coronavirus pandemic in Illinois and in other jurisdictions in the United States and worldwide. Currently, the Company is consequently aware of changes in its business as a result of the coronavirus pandemic, but uncertain of the impacts of those changes on its consolidated statements of position, operations or cash flows. As of the date of this filing, we are reasonably confident in customer demand through 2020 and in to the first quarter of 2021. Demand for the second quarter of 2021, and the subsequent quarter, is not yet clear to management. We believe the resulting cessations, reductions, and disruptions in its customers’ and suppliers’ operations could be temporary; however, the Company’s management also believes the duration and, hence, the potential impact of such cessations, reductions, and disruptions is currently unknowable. As a result, although we believe we have acceptable visibility through the first quarter of 2021, conditions are fluid and our estimates regarding the first quarter and beyond could prove inaccurate. Moreover, we are unable to clearly estimate the potential impact on our business for the balance of the year as of the date of this filing.

These circumstances raise significant doubt as to the Company’s ability to operate as a going concern under U.S. GAAP. The accompanying financial statements have been prepared on a going concern basis in accordance with U.S. GAAP. As such, no adjustments have been made to the unaudited condensed consolidated financial statements for the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue operating as a going concern.

On April 17, 2020, the Company received funding in the form of a loan under the “PPP,” under Division A, Title I of Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), in the amount of $952 which helped us to continue to pay our people, rent and utilities during the second quarter. Under the PPP, the Company may apply for forgiveness of the amount due on the loan in an amount equal to the sum of the following costs incurred during the 24-week period beginning on the date of the first disbursement of the Loan: (a) payroll costs, (b) any payment of interest on a covered obligation (which shall not include any prepayment of or payment of principal on a covered mortgage obligation), (c) any payment on a covered rent obligation, and (d) any covered utility payment, calculated in accordance with the terms of the CARES Act. No assurance can be provided that the Company will obtain forgiveness of the Loan in whole or in part. The principal amount of the PPP note accrues interest at the rate of 1.00% per year. The Company will be required to pay any unforgiven principle and interest under the PPP note in eighteen equal monthly installments, with the first payment being due on a date yet to be determined. The Company is in the process of applying for loan forgiveness and does not expect resolution until the first quarter of 2021.

(3) Description of Business

Nanophase Technologies Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”) is a scientifically-driven company which, along with its wholly-owned subsidiary, Solésence, LLC (our “Solésence^®subsidiary”), is focused in various beauty- and life-science markets. Skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy. We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in material engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of markets in skin care, including for use in sunscreens as active ingredients and as fully developed prestige skin care products, marketed and sold through our Solésence^® subsidiary. In terms of our life sciences focus, we have seen current conditions significantly increase demand for our medical diagnostics ingredients, as testing for various viruses, most notably Covd-19, has become a critical use of our technology. Additionally, we continue to sell products in markets for architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications— all of which, along with medical diagnostics, fall into the advanced materials product category.

We target markets, primarily related to skin health products and ingredients, and diagnostic life sciences ingredients where we believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with current customers in these target markets to identify their material and performance requirements and market our materials to various end-use applications manufacturers, and our Solésence^® products to cosmetics and skin care brands. Over the past few years, we have expanded our marketing efforts for our Solésence products and are seeing more customers responding to our successful products being sold into their markets. Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Active Stress Defense ™ Technology — which became the cornerstone of our new product development in personal care, with first revenue recognized during 2016. In addition, through the creation of our Solésence^® subsidiary, we utilize this particle surface treatment to manufacture and sell fully developed solutions to targeted customers in the skin care industry, in addition to the ingredients we have traditionally sold in the personal care area.

Although our primary strategic focus has been the North American market, we currently sell material to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX.

While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products.

(4) Revenues

Revenues are recognized at a point in time, typically when control of the promised goods is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods.

Deferred revenue includes customer deposits and other receipts that are recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in the Company’s Consolidated Condensed Statement of Operations. Customer deposits, $309 as of September 30, 2020, have been classified as deferred revenue. At December 31, 2019, customer deposits amounted to $575.

On July 31, 2019, we entered into a Joint Development Agreement (“JDA”), with an initial term of ten years, with Sumitomo Corporation of Americas (“SCOA”) to jointly develop certain coated materials for the use in the personal care market. In return for the Company’s exclusive efforts on SCOA’s behalf, SCOA has paid a commitment fee of $250 and will pay two subsequent payments, of $125 each, for the development of products. The two subsequent payments are contingent upon the achievement of certain performance obligations as defined in the agreement. We began recognizing revenue from the commitment fee in November 2019 and will continue to do so as we fulfill our contractual performance obligations. In the case of the SCOA JDA, the Company is recognizing revenue over time using an input method. If the Company elects to terminate the agreement within the terms allowed and prior to achieving the initial performance obligations, the original $250 must be refunded.

As of September 30, 2020, the Company has recognized $250 in cumulative revenue from the SCOA JDA, of which $47 and $229 was recognized in the three and nine months ended September, 30 of 2020. The Company has recognized this revenue proportionally, based upon its estimate of the period over which the performance obligation is expected to be completed.

(5) Earnings Per Share

Options to purchase approximately 165,000 and 497,000 shares of common stock that were outstanding as of September 30, 2019 were not included in the computation of loss per share for the three and nine months ended September 30, 2019, respectively, as the impact of such shares would be anti-dilutive.

(6) Financial Instruments

We follow the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.

Our financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, along with the promissory note with no related borrowings described in Note 7, and any borrowings on the working capital line of credit from Libertyville Bank and Trust and any borrowings under the Master Agreement from Beachcorp, LLC described below in Note 7. The fair values of all financial instruments were not materially different from their carrying values. There were no financial assets or liabilities adjusted to fair value on September 30, 2020 or December 31, 2019.

(7) Notes and Line of Credit

During July 2014 we entered into a bank-issued letter of credit and related promissory note for up to $30 in borrowings to support our obligations under our facility lease agreement. No borrowings have been incurred under this promissory note. Should any borrowings occur in the future, the interest rate would be the prime rate plus 1%, with the bank having the right to “set off” or apply unpaid balances against our checking account if we fail to meet our obligations under any borrowings under the note. It is our intention to renew this note annually, for as long as we need to do so pursuant to the terms of our facility lease agreement. This note was renewed through July 1, 2021. Because there were no amounts outstanding on the note at any time during 2020 or 2019, we have recorded no related liability on our balance sheet.

On March 22, 2019, we executed a Business Loan Agreement, dated as of March 4, 2019 (the “Loan Agreement”), with Libertyville Bank and Trust Company, a Wintrust Community Bank (“Libertyville”), our primary bank, the maturity of which was extended until April 20, 2021 pursuant to an amended and restated Promissory Note executed on June 25, 2020, and dated as of April 4, 2020. Under the Loan Agreement, Libertyville will provided a maximum of (i) $500 or (ii) two times the sum of (a) 75% our eligible accounts receivables and (b) our cash deposited with Libertyville, whichever is less, of revolving credit to us, collateralized by a senior priority lien on our accounts receivable, inventory, equipment, general intangibles and fixtures. Interest was payable monthly on any advances at a floating interest rate of the prime rate at the time plus 1%. We are required to have $500 in cash, inclusive of the borrowed amount, at Libertyville on the date of any advance. Advances could only occur at the beginning or end of a fiscal quarter and were required to be repaid in full within five business days of the advance. We borrowed $500 on September 29, 2020 and repaid it on October 2, 2020. We borrowed $500 on June 29, 2020 and repaid it on July 1, 2020. We borrowed $500 on March 30, 2020 and repaid it on April 2, 2020. We borrowed $500 on December 31, 2019 and repaid it on January 2, 2020.

On November 16, 2018, we entered into a Business Loan Agreement (the “Master Agreement”) with Beachcorp, LLC. Beachcorp, LLC is managed by Bradford T. Whitmore, who, together with his affiliates Grace Brothers, Ltd. and Grace Investments, Ltd., beneficially owned approximately 63% of the outstanding shares of our common stock as of September 30, 2020. The Master Agreement relates to two loan facilities, each evidenced by separate promissory notes, each dated November 16, 2018: a term loan to the Company of up to $500 to be disbursed in a single advance (the “Term Loan”) with a fixed annual interest rate of 8.25%, payable quarterly, accruing from the date of such advance and with principal due on December 31, 2020; and an asset-based revolving loan facility for the Company of up to $2,000 (the “Revolver Facility”), with floating interest accruing at the prime rate plus 3% (8.25% minimum) per year, with a borrowing base consisting of qualified accounts receivable of the Company, and with all principal and accrued interest initially to be due March 31, 2020. On March 23, 2020, the Company and Beachcorp, LLC executed the First Amendment to our Master Agreement that extends the maturities of both the Term Loan and the Revolver Facility to March 31, 2021. On September 8, 2020, the Company executed an updated Promissory Note to, and a Second Amendment to the Business Loan Agreement with Beachcorp, LLC, expanding the capacity of the Revolver Facility from $2,000 to $2,750. The Term Loan and Revolver Facility are secured by all the unencumbered assets of the Company and subordinated to Libertyville’s secured interest under the New Business Loan Agreement. The Master Agreement substantially restricts the Company’s ability to incur additional indebtedness during the terms of both the Term Loan and the Revolver Facility. On September 30, 2020, the balance on the term loan was $500 and the balance on the Revolver Facility was $1,541. There was $34 in related interest expense during the quarter ended September 30, 2020, of which $12 was accrued and $22 paid by the end of the quarter. There was $47 in related interest expense during the quarter ended September 30, 2019, of which $9 was accrued and $18 paid by the end of the quarter. As Beachcorp, LLC is an affiliate of Mr. Whitmore, this amounts to interest to be paid to a related party. On September 30, 2020, the Company had $734 in excess borrowing capacity over the $1,541 balance on the Revolver Facility. The balance of borrowing base, loan amount, and any excess payments required over the available borrowing base will change as frequently as daily, given the operational nature of the elements of the Revolver Facility.

On November 20, 2019, we entered into a 2% Secured Convertible Promissory Note with Bradford T. Whitmore in the principal amount of $2,000 (the “Convertible Note”). The principal amount is payable in a single payment on May 15, 2024 (the “Maturity Date”). The principal amount of the Convertible Note accrues interest at the rate of 2.0% per year, which interest is payable semi-annually on the 15th day of May and November, commencing on May 15, 2020. The principal amount and, at the holder’s option, accrued interest under the Convertible Note is convertible at the holder’s option into additional shares of the Company’s common stock in whole or in part and from time to time up to the Maturity Date at a conversion price of $0.20 per share. The convertible note contains a beneficial conversion feature since the Company’s stock was trading at $0.32 per share on the date the Company entered into the agreement. The intrinsic value of the beneficial conversion feature was $1.2 million on November 20, 2019 and is recorded as a discount on the convertible note. The discount will be accreted to the convertible note over the life of the note using the straight-line method. The offset to these discounts will be interest expense. For the three and nine months ended September 30, 2020, the Company accreted $67 and $200, respectively. The balance on the convertible note was $1,030 and $830, net of discounts of $1,103 and $1,170 at September 30, 2020 and December 31, 2019, respectively.

On September 30, 2020, the balance on the term loan was $500, the balance on the Revolver Facility was $1,541, the balance on the Convertible Note was $2,000. In the nine months ended September 30, 2020, there was $334 in interest expense relating to these credit facilities held by Beachcorp, LLC. The accrued interest expense balance on these related party credit facilities amounted to $27, and $10, at September 30, 2020 and December 31, 2019, respectively. The obligations under the Convertible Note are secured by a security interest in all of the Company’s personal property pursuant to a Commercial Security Agreement among Mr. Whitmore, the Company and Solésence, LLC, the Company’s sole subsidiary. Given that Beachcorp, LLC is an affiliate of Mr. Whitmore, this amounts to all of this interest being owed to a related party.

On April 17, 2020, we entered into a Promissory Note, dated as of April 16, 2020, in favor of Libertyville in the principal amount of $952 for our loan under the PPP. The Company may apply for forgiveness of the amount due on the loan in an amount equal to the sum of the following costs incurred during the 24-week period beginning on the date of the first disbursement of the Loan: (a) payroll costs, (b) any payment of interest on a covered obligation (which shall not include any prepayment of or payment of principal on a covered mortgage obligation), (c) any payment on a covered rent obligation, and (d) any covered utility payment, calculated in accordance with the terms of the CARES Act. No assurance can be provided that the Company will obtain forgiveness of the Loan in whole or in part. The principal amount of the PPP note accrues interest at the rate of 1.00% per year. The Company will be required to pay any unforgiven principle and interest under the PPP note in eighteen equal monthly installments, with the first payment being due on November 17, 2020 and continuing on the same day of each subsequent month until April 17, 2022. On September 30, 2020, the balance under the PPP note was $952.

(8) Inventories

Inventories consist of the following:

	September 30, 2020			December 31, 2019
Raw materials	$	2,187		$	1,425
Finished goods		1,427			1,170
		3,614			2,595
Allowance for excess inventory quantities		(30	)		(41	)
	$	3,584		$	2,554

(9) Leases

The Company's operating lease portfolio is comprised of operating leases for office, warehouse space and equipment. Certain of the Company's leases include one or more options to renew or terminate the lease at the Company's discretion. The Company regularly evaluates the renewal and termination options and when they are reasonably certain of exercise, includes the renewal or termination option in our lease term.

As of September 30, 2020, the operating lease right-of-use “ROU” asset had a balance of $1,917 which is included in the “Operating lease right-of-use assets” line item of these condensed consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $411 and $1,766 respectively. As of December 31, 2019, the ROU asset had a balance of $2,119 which is included in the “Operating lease right-of-use assets” line item of these condensed consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $357 and $2,035 respectively. These are included in the “Current portion of operating lease obligations” and “Long-term operating lease obligations, net of current portion” line items of these condensed consolidated financial statements. The discount rates used for leases accounted for under ASC 842 are based on an interest rate yield curve developed for the leases in the Company’s portfolio.

The office leases contain variable lease payments which consist primarily of rent escalations based on an established index or rate and taxes, insurance, and common area or other maintenance costs, which are paid based on actual costs incurred by the lessor.

Quantitative information regarding the Company’s leases is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Components of lease cost
Finance lease cost components:
Amortization of finance lease assets	$	17	$	18	$	54	$	52
Interest on finance lease liabilities		9		14		30		44
Total finance lease costs	$	26	$	32	$	84	$	96
Operating lease cost components:
Operating lease cost	$	140	$	129	$	425	$	375
Variable lease cost		27		27		81		81
Short-term lease cost		10		16		12		68
Total operating lease costs	$	177	$	172	$	518	$	524
Total lease cost	$	203	$	204	$	602	$	620

Supplemental cash flow information related to leases is as follows for the nine months ended:

	September 30, 2020			September 30, 2019
Cash paid for amounts included in the measurement of liabilities:
Operating cash outflow from operating leases	$	518		$	509
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	—		$	205
Weighted-average remaining lease term-finance leases (in years)		1.9			2.2
Weighted-average remaining lease term-operating leases (in years)		3.4			3.3
Weighted-average discount rate-finance leases		9.3	%		9.1	%
Weighted-average discount rate-operating leases		14.3	%		14.4	%

The future maturities of the Company’s finance and operating leases as of September 30, 2020 is as follows:

	Finance Leases			Operating Leases			Total
2020	$	63		$	172		$	235
2021		196			701			897
2022		109			720			829
2023		5			705			710
2024		—			595			595
2025 and thereafter		—			1			1
Total payments	$	373		$	2,894		$	3,267
Less amounts representing interest		(39	)		(717	)		(756	)
Total minimum payments required:	$	334		$	2,177		$	2,511

(10) Share-Based Compensation

We follow FASB ASC Topic 718, Compensation – Stock Compensation, in which compensation expense is recognized only for share-based payments expected to vest. We recognized compensation expense related to stock options of $48 and $147 for the three and nine months ended September 30, 2020, respectively, compared to $64 and $179 for the three and nine months ended September 30, 2019, respectively.

As of September 30, 2020, there was approximately $290 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under our stock option plans. That cost is expected to be recognized over a remaining weighted-average period of 1.8 years.

Stock Options and Stock Grants

During the nine months ended September 30, 2020, 78,277 stock options were exercised for $23. During the nine months ended September 30, 2019, 36,000 stock options were exercised for $16. During the nine months ended September 30, 2020, 535,000 stock options were granted, compared to 547,500 stock options granted during the same period in 2019. During the nine months ended September 30, 2020, 460,640 stock options expired compared to 130,500 for the same period in 2019. For the nine months ended September 30, 2020, 202,134 stock options were forfeited compared to 48,600 for the same period in 2019. We had 3,507,073 stock options outstanding at a weighted average exercise price of $0.58 on September 30, 2020, compared to 3,747,400 stock options outstanding at a weighted average exercise price of $0.64 on September 30, 2019.

No stock options were granted in the three-month periods ending September 30, 2020 and 2019.

The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for stock options granted during the nine months periods presented:

For the nine months ended	September 30, 2020			September 30, 2019
Weighted-average risk-free interest rates		0.5	%		2.3	%
Dividend yield		0.00	%		0.00	%
Weighted-average expected life of the option		7 years			7 years
Weighted-average expected stock price volatility		94	%		94	%
Weighted-average fair value of the options granted	$	0.36		$	0.41

As of September 30, 2020, we did not have any unvested restricted stock or performance shares outstanding.

(11) Significant Customers and Contingencies

Revenue from four customers constituted approximately 30%, 18%, 16% and 16%, respectively, of our total revenue for the three months ended September 30, 2020. For the nine months ended September 30, 2020, revenue from the same four customers was approximately 20%, 32%, 13% and 14%, respectively. Amounts included in accounts receivable on September 30, 2020 relating to these four customers were approximately $901, $328, $291 and $420, respectively. Revenue from these four customers constituted approximately 0%, 75%, 0% and 4%, respectively, for the three months ended September 30, 2019. For the nine months ended September 30, 2019, revenue from the same four customers was approximately 4%, 64%, 0%, and 9%, respectively. Amounts included in accounts receivable on September 30, 2019 relating to these four customers were approximately $0, $1,042, $0 and $122, respectively. The loss of one of these significant customers, a significant decrease in revenue from one or more of these customers, or the failure to attract new customers could have a material adverse effect on our business, results of operations and financial condition.

We currently have exclusive supply agreements with BASF Corporation (“BASF”), our largest customer, that have contingencies outlined which could potentially result in the license of technology and/or the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements, certain other obligations and/or certain financial condition covenants. The financial condition covenants in one of our supply agreements with BASF “trigger” a technology transfer right (license and equipment sale at BASF’s option) in the event (a) that earnings for the twelve-month period ending with our most recently published quarterly financial statements are less than zero and a minimum of $1 million in total of certain assets of which at least $500 must be in cash, cash equivalents and certain investments, with the balance being composed of certain inventory and receivables, is not maintained or (b) of an acceleration of any debt maturity having a principal amount of more than $10 million. There are certain minimum finished goods inventory requirements with the 2019 amendment to the supply agreement. This agreement also requires Nanophase to maintain certain finished goods inventory levels as “safety stock,” beginning in the first quarter of 2019, and increasing through the third quarter of 2019 to a negotiated level based on agreed demand metrics, in order to maintain the $500 non-cash component discussed above. After September 30, 2019, should our safety stock fall below the prescribed amount of material, the quarter-end cash requirement would revert to $1,000 in cash, cash equivalents, and certain investments. The safety stock requirement may be adjusted upon mutual agreement.

Our supply agreements with BASF also “trigger” a technology transfer right in the event of our insolvency, as further defined within the agreements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either 115% of the equipment’s net book value or the greater of 30% of the original book value of such equipment, and any associated upgrades to it, or 115% of the equipment’s net book value, depending on the equipment and related products.

We expect to expend resources on research, development and product testing, and in expanding current capacity or capability for new business. In addition, we may incur significant costs in preparing, filing, prosecuting, maintaining and enforcing our patents and other proprietary rights. We may need additional financing if we were to lose an existing customer or suffer a significant decrease in revenue from one or more of our customers or because of currently unknown capital requirements, new regulatory requirements or the need to meet the cash requirements discussed above to avoid a triggering event under our BASF agreement. Given our expected growth in our Solésence® business, we may also have temporary working capital demands that we cannot fund with existing capital, while remaining in compliance with the covenants included in our BASF agreement described above. If necessary, we may seek funding through public or private financing and through contracts with governmental entities or other companies. Additional financing may not be available on acceptable terms or at all, and any such additional financing could be dilutive to our shareholders. If we are unable to obtain adequate funds, we may be required to delay, scale-back or eliminate some of our manufacturing and marketing operations or we may need to obtain funds through arrangements on less favorable terms. Such circumstances could raise doubt as to our ability to continue as a going concern. If we obtain funding on unfavorable terms, we may be required to relinquish rights to some of our intellectual property.

(12) Business Segmentation and Geographical Distribution

Revenue from international sources approximated $1,242 and $2,747 for the three and nine months ended September 30, 2020, respectively, compared to $33 and $734 for the three and nine months ended September 30, 2019, respectively. All of this revenue was product revenue.

Our operations comprise a single business segment and all our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence®. The revenues for the three months and nine months ended September 30, 2020 and 2019, by category, are as follows:

	For the three months ended September 30,				For the nine months ended September 30,
Product Category	2020		2019		2020		2019
Personal Care Ingredients	$	753	$	2,304	$	4,190	$	6,464
Advanced Materials		1,582		388		3,678		1,988
Solésence®		1,553		377		4,394		1,666
Total Sales	$	3,888	$	3,069	$	12,262	$	10,118

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

Nanophase is a scientifically driven company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence^®subsidiary”), is focused in various beauty- and life-science markets. Skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy. We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in material engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of markets in skin care, including for use in sunscreens as active ingredients and as fully developed prestige skin care products, marketed and sold through our Solésence^® subsidiary. In terms of our life sciences focus, we have seen current conditions significantly increase demand for our medical diagnostics ingredients, as testing for various viruses, most notably Covd-19, has become a critical use of our technology. Additionally, we continue to sell products in markets for architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications— all of which, along with medical diagnostics, fall into the advanced materials product category.

With the current circumstances of, and the impact of the various reactions and policies relating to, the Covid-19 pandemic, it is currently management’s belief that we will continue to achieve growth in Solésence® sales through 2020. We are also expecting additional Solésence growth in 2021, but management believes the outlook in to 2021 remains uncertain, with a continuation of the Covid-19 pandemic and related reactions and policies having the potential to limit new product sales growth, and having further potential negative impact on the Company, its customers, and the markets it serves.

It is also management’s belief that the Covid-19 pandemic, related governmental reaction, and resulting economic slow-down has, and is expected to continue, to affect certain consumer behaviors and markets. This has had a negative impact on our Personal Care Ingredients business during 2020, and could continue to some extent in to 2021. Management believes the negative impacts in the fourth quarter and, if applicable, thereafter, are not currently quantifiable.

Results of Operations

Total revenue increased to $3,888 for the three months ended September 30, 2020, compared to $3,069 for the same period in 2019. Total revenue increased to $12,262 for the nine months ended September 30, 2020 from $10,118 for the same period in 2019. A substantial majority of our revenue for both periods was from our largest customers, in particular, sales to our largest customer in personal care and sunscreen applications. Revenue from our top four customers constituted approximately 30%, 18%, 16% and 16%, respectively, of our total revenue for the three months ended September 30, 2020, and approximately 20%, 32%, 13% and 14%, respectively, for the nine months ended September 30, 2020. Revenue from these four customers constituted approximately 0%, 75%, 0% and 4%, respectively, for the three months ended September 30, 2019 and approximately 4%, 64%, 0% and 9%, respectively, for the nine months ended September 30, 2019. Product revenue, the primary component of our total revenue, increased to $3,827 for the three months ended September 30, 2020, compared to $3,043 for the same period in 2019. The increase was primarily due to sales to Roche Laboratories for Covid19 testing kits. Product revenue increased to $11,929 for the nine months ended September 30, 2020, compared to $9,797 for the same period in 2019. Solésence® product revenue increased approximately 164% for the nine months ended September 30, 2020 compared to the same period for 2019. The total increase in product revenue is attributed to increased sales of our Solésence products and ingredients sold to Roche Diagnostics, offset by significantly reduced sales of sunscreen actives into our Personal Care Ingredients markets through our largest customer.

Other revenue increased to $61 for the three months ended September 30, 2020, compared to $26 for the same period in 2019. Other revenue increased to $333 for the nine months ended September 30, 2020, compared to $321 for the same period in 2019. Other revenue is typically comprised of royalties and shipping costs paid by customers. Shipping revenue in 2020 is included in product revenue. For the nine months ended September 30, 2019, other revenue included a unique bulk buyout of $211 in Q1 of 2019.

Cost of revenue generally includes costs associated with commercial production and customer development arrangements. Cost of revenue decreased to $2,201 for the three months ended September 30, 2020, compared to $2,506 for the same period in 2019. Cost of revenue decreased to $7,832 for the nine months ended September 30, 2020, compared to $7,839 for the same period in 2019. The decrease in cost of revenue was primarily driven by manufacturing efficiencies related to Solésence® products coupled with lower managerial payroll offset by price inflation on materials. While we typically pass through costs to our customers, we sometimes cannot pass through 100% of pricing increases on raw materials, and even with pass throughs, our gross margin percentage is negatively impacted by higher material costs.

We expect to continue new advanced material development relating to personal care ingredients, medical diagnostic materials, and for our formulated Solésence® products through 2020 and beyond. At current revenue levels we have generated a positive gross margin, though margins are greatly impacted by revenue volume, with higher volumes generally allowing for better absorption of manufacturing overhead. The extent to which margins may grow, as a percentage of total revenue, will be dependent upon revenue mix, revenue volume, our ability to manage costs and pass commodity market-driven raw materials increases on to customers, and the speed and efficiency with which we are able to scale up production for our Solésence® products. We expect that product revenue volume increases will result in our fixed manufacturing costs being more efficiently absorbed, which should lead to increased margins. We expect to continue to focus on reducing controllable variable product manufacturing costs, with potential variability related to the commodity metals markets, but may or may not realize absolute dollar gross margin growth through 2020 and beyond, dependent upon the factors discussed above.

Research and development expense, which includes all expenses relating to the technology and advanced engineering groups, primarily consists of costs associated with the development or acquisition of new product applications, and finished product formulations for our Solésence® business. As an example, we have been, and continue to be, engaged in product development work for our new fully formulated finished skincare products marketed through Solésence®. Much of this work has led to several new products and additional potential new products. We also engage in in-vitro, ex-vivo, and in-vivo tests to determine the efficacy of our Solésence® products, as well as to provide our customers with support for a consumer claims set. We are not certain when or if any significant revenue will be generated from the production of the materials described above.

Research and development expense decreased to $405 for the three months ended September 30, 2020, compared to $488 for the same period in 2019. For the nine months ended September 30, 2020 research and development expense decreased to $1,134 compared to $1,450 for the same period in 2019.

The main reasons for this decrease was a reduction in total staffing (not filling empty positions during the ongoing Covid-19 pandemic) and a reduction on outside testing costs incurred as our Solésence® products have entered the market and the current testing requirements are lower than they were during our startup phase. Legal expenses pertaining to intellectual property, also part of research and development expense, were up for the nine-month period.

Selling, general and administrative expense decreased to $730 for the three months ended September 30, 2020, compared to $890 for the same period in 2019. For the nine months ended September 30, 2020, selling, general and administrative expense decreased to $2,133 compared to $2,711 for the same period in 2019.

For both the three- and nine-month periods in 2020, compensation expense was down due to a reorganization of some of the functions in this area, consulting expenses were lower due, to a great extent the initial Solésence® launch work has been completed, and travel and entertainment expenses were down as a product of the ongoing Covid-19 pandemic and its impact on air travel, live trade shows, and in-person meetings.

Inflation

We believe inflation has not had a material effect on our operations or financial position. However, supplier price increases and wage and benefit inflation, both of which represent a significant component of our costs of operations, may have a material effect on our operations and financial position in 2020 and beyond if we are unable to pass through any applicable increases under our present contracts or through to our markets in general.

Liquidity and Capital Resources

Our cash and cash equivalents amounted to $1,134 on September 30, 2020, compared to $1,194 on December 31, 2019 and $962 on September 30, 2019. The net cash used in our operating activities was $1,732 for the nine months ended September 30, 2020, compared to $2,161 for the same period in 2019. The net use of cash during both periods was driven primarily by a significant increase in accounts receivable between the beginning and end of each period. In 2019, we also had a net loss of $2,022, which contributed further to the use of cash during the nine months ended September 30, 2019. Net cash used in investing activities, specifically capital expenditures, was $448 during the nine months ended September 30, 2020, compared to $523 for the nine months ended September 30, 2019. Net cash provided by financing activities was $2,120 and $2,301 during the nine months ended September 30, 2020, and 2019, respectively. We paid $172 for capital lease obligations during the nine months ended September 30, 2020 compared to $162 in the same period in 2019.

On June 25, 2020 we executed a new promissory note with Libertyville to extend the maturity under our Business Loan Agreement until April 4, 2021. We paid the outstanding balance of $500 in January 2020 and had borrowings under our line of credit with Libertyville of $500 on June 30, 2020, and September 30, 2020, which were subsequently repaid in July, 2020 and October 2020, respectively.

On May 13, 2019, we sold approximately 4.2 million shares of our unregistered common stock to our largest investor for approximately $1,700 in proceeds. No selling commission or other remuneration was paid in connection with this transaction. We have used the proceeds for general corporate purposes.

In November 2019, we entered in to a 2% Convertible Promissory Note in the original principal amount of $2,000. This note matures on May 15, 2024 and is payable to our investor at that time in cash, or through conversion of the rights to purchase up to 10,000,000 unregistered shares of the Company’s common stock at $0.20 per share. The conversion can be done in full or in part and may be undertaken prior to the note’s maturity date.

On April 17, 2020, we received a loan of $952 from Libertyville under the PPP. Under the PPP, the Company may apply for forgiveness of the amount due on the loan in an amount equal to the sum of the following costs incurred during the 24-week period beginning on the date of the first disbursement of the Loan: (a) payroll costs, (b) any payment of interest on a covered obligation (which shall not include any prepayment of or payment of principal on a covered mortgage obligation), (c) any payment on a covered rent obligation, and (d) any covered utility payment, calculated in accordance with the terms of the CARES Act. Although management believes that the Company expended the proceeds of the PPP loan principally for forgivable purposes under the CARES Act, no assurance can be provided that the Company will obtain forgiveness of the PPP loan in whole or in part.

The Master Agreement substantially restricts the Company’s ability to incur additional indebtedness during the terms of the Term Loan, the Revolver Facility, and the Convertible Promissory Note. On September 30, 2020, the balances on the Term Loan and the Convertible Promissory Note were $500 and $2,000, respectively, the balance on the Revolver Facility was $1,541 and the balance of the PPP loan was $952.

Our supply agreements with our largest customer, BASF, contain certain financial covenants which could potentially impact our liquidity. The most restrictive financial covenants under these agreements require that we maintain a minimum of $1 million in total of certain assets of which at least $500 must be in cash, cash equivalents, and certain investments, with the balance being composed of certain inventory and receivables, and that we not have the acceleration of any debt maturity having a principal amount of more than $10 million, in order to avoid triggering the customer’s potential right to transfer certain technology and equipment to that customer at a contractually-defined price. We had approximately $1,134 in cash on September 30, 2020. This supply agreement and its covenants are more fully described in Note 11, and our credit facilities are more fully described in Note 7, to our Financial Statements in Part I, Item 1 of this Form 10-Q.

We believe that cash from operations and cash on hand, in addition to unused borrowing capacity, should be adequate to fund our operating plans through 2020. Given our expected growth in our Solésence^® business, we are monitoring the temporary working capital demands that this could create, with timing being the most critical variable. Our actual future capital requirements in 2020 and beyond will depend on many factors, including customer acceptance of our current and potential advanced materials, applications and product, continued progress in research and development activities and product testing programs, the magnitude of these activities and programs, the costs necessary to increase and expand our manufacturing capabilities and to market and sell our advanced materials, applications and products, and the impacts of the Covid-19 pandemic and related reactions and policies if those impacts do not substantially improve in 2021 and continuing thereafter.

Other important issues that will drive future capital requirements will be the development of new markets and new customers as well as the potential for significant unplanned growth with existing customers. Depending on the success of certain projects, we expect that capital spending relating to currently known capital needs for the remainder of 2020 will be between $250 and $500, and we could enter into one or more financing leases to finance these acquisitions, subject to the provisions of our Loan Agreement with Libertyville and our Master Agreement relating to our business loans with Beachcorp, LLC. If the Company’s demand from customers is significantly lower than expected prior to the commencement of the Covid-19 Pandemic, if those projects are delayed or ultimately prove unsuccessful, or if we fail to obtain financing on terms acceptable to us, we would expect our capital spending to be below the lower end of that range. Similarly, substantial success in business development projects may cause the actual capital investment for the remainder of 2020 to exceed the top of this range.

Should events arise that make it appropriate for us to seek additional financing, such additional financing may not be available on acceptable terms or even at all, and any such additional financing could be dilutive to our stockholders. Such financing could be necessitated by such things as the loss of one or more existing customers; a significant decrease in revenue from one or more of our customers; temporary working capital demands resulting from our expected growth in our Solésence^® business that we cannot fund with existing capital; currently unknown capital requirements in light of the factors described above; new regulatory requirements that are outside our control; the need to meet previously discussed cash requirements to avoid a triggering event under our BASF agreement; the continuation of the Covid-19 pandemic and related reactions and policies after the fourth quarter of 2020; or various other circumstances coming to pass that we currently do not anticipate. The failure to have access to sufficient capital to fund our business plans may result in a curtailment or other change in those plans, and under such circumstances, may raise doubt as to our ability to continue as a going concern.

On September 30, 2020, we had a net operating loss carryforward of approximately $77 million for income tax purposes. Because we may have experienced "ownership changes" within the meaning of the U.S. Internal Revenue Code in connection with our various prior equity offerings, future utilization of this carryforward may be subject to certain limitations as defined by the Internal Revenue Code. If not utilized, the carryforward will expire at various dates between January 1, 2020 and December 31, 2036. Under recent changes in the Internal Revenue Code, losses incurred after January 1, 2018 carry forward indefinitely. As a result of the annual limitation and uncertainty as to the amount of future taxable income that will be earned prior to the expiration of the carryforward, we have concluded that it is likely that a substantial portion of this carryforward will expire before ultimately becoming available to reduce income tax liabilities. Changes in Illinois state law that began in 2011 will impact net loss carryforward duration and utilization on the state tax level.

Off−Balance Sheet Arrangements

We have not created, and are not party to, any special-purpose or off-balance sheet entities for the purposes of raising capital, incurring debt or operating our business. We do not have any off-balance sheet arrangements or relationships with entities that are not consolidated into our financial statements that are reasonably likely to materially affect our liquidity or the availability of capital resources.

As more fully described in Note 7 to our Financial Statements, in Part I, Item I of this Form 10-Q, during 2014 we entered into a letter of credit and promissory note for up to $30 supporting our obligations under our facility lease agreement. No borrowings have been incurred under this promissory note.

Safe Harbor Provision

We want to provide investors with more meaningful and useful information. As a result, this Quarterly Report on Form 10-Q (the "Form 10-Q") contains and incorporates by reference certain "forward-looking statements", as defined in Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements reflect our current expectations of the future results of our operations, performance and achievements. Forward-looking statements are covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We have tried, wherever possible, to identify these statements by using words such as "anticipates", "believes", "estimates", "expects", "plans", "intends" and similar expressions. These statements reflect management's current beliefs and are based on information now available to it. Accordingly, these statements are subject to certain risks, uncertainties and contingencies that could cause our actual results, performance or achievements in 2020 and beyond to differ materially from those expressed in, or implied by, such statements. These risks, uncertainties and factors include, without limitation: our ability to be consistently profitable despite the losses we have incurred since our incorporation; a decision by a customer to cancel a purchase order or supply agreement in light of our dependence on a limited number of key customers; the terms of our supply agreements with BASF, which could trigger a requirement to transfer technology and/or sell equipment to that customer; our potential inability to obtain working capital when needed on acceptable terms or at all; our ability to obtain materials at costs we can pass through to our customers, including Rare Earth elements, specifically cerium oxide, as well as high purity zinc; uncertain demand for, and acceptance of, our nanocrystalline materials and Solésence® products; our manufacturing capacity and product mix flexibility in light of customer demand; our limited marketing experience, including with our suite of Solésence® products; changes in development and distribution relationships; the impact of competitive products and technologies; our dependence on patents and protection of proprietary information; the resolution of litigation or other legal proceedings in which we may become involved; our ability to maintain an appropriate electronic trading venue for our securities; the impact of any potential new governmental regulations that could be difficult to respond to or costly to comply with; and the development and continuation of the ongoing Covid-19 pandemic and related reactions and policies. In addition, our forward-looking statements could be affected by general industry and market conditions and growth rates. Readers of this Quarterly Report on Form 10-Q should not place undue reliance on any forward-looking statements. Except as required by federal securities laws, we undertake no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required for a smaller reporting company.

Item 4. Controls and Procedures

Disclosure controls

We are responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed by us in the reports filed by us under the Exchange Act is: (a) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms; and (b) accumulated and communicated to our management, including our principal executive and principal financial officers, to allow timely decisions regarding required disclosures. It should be noted that in designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and that our management necessarily was required to apply its judgment regarding the design of our disclosure controls and procedures. As of the end of the period covered by this report, we conducted an evaluation, under the supervision (and with the participation) of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at reaching that level of reasonable assurance.

Internal control over financial reporting

The Company’s management, including the CEO (who is also currently acting as both the Company’s principal executive officer and the Company’s principal financial officer), confirm that there was no change in the Company’s internal control over financial reporting during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are not a party to any pending legal proceedings or claims that we believe will result in a material adverse effect on our business, financial condition, or operating results.

Item 1A. Risk Factors

Not required for a smaller reporting company.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

	Exhibit 10.1	Second Amendment to Business Loan Agreement, dated September 16, 2020, between the Company and Beachcorp, LLC, incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed September 22, 2020.

	Exhibit 31.1	Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act.

	Exhibit 31.2	Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act.

	Exhibit 32	Certification of the Chief Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350.

	Exhibit 101	The following materials from Nanophase Technologies Corporation’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, formatted in XBRL (Extensible Business Reporting Language): (1) the Balance Sheets, (2) the Statements of Operations, (3) the Statements of Shareholders Equity, (4) the Statements of Cash Flows, and (5) the Notes to Unaudited Consolidated Condensed Financial Statements

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	NANOPHASE TECHNOLOGIES CORPORATION

Date: November 16, 2020		By:	/s/ JESS A. JANKOWSKI
			Jess A. Jankowski
			President and Chief Executive Officer
			(principal executive officer, and principal financial officer)

EX-31.1 2 ex31-1.htm CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Nanophase Technologies Corporation 10-Q

Exhibit 31.1

Certification of the Chief Executive Officer Pursuant to

Rules 13a-14(a) and 15d-14(a) under the Exchange Act

I, Jess A. Jankowski, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Nanophase Technologies Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 16, 2020
	/s/ JESS A. JANKOWSKI
	Jess A. Jankowski
	(principal executive officer, and principal financial officer)

EX-31.2 3 ex31-2.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

Nanophase Technologies Corporation 10-Q

Exhibit 31.2

Certification of the Principal Financial Officer Pursuant to

Rules 13a-14(a) and 15d-14(a) under the Exchange Act

I, Jess Jankowski, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Nanophase Technologies Corporation;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 16, 2020
	/s/ JESS A. JANKOWSKI
	Jess A. Jankowski
	(principal executive officer, and principal financial officer)

EX-32 4 ex32.htm CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

Nanophase Technologies Corporation 10-Q

Exhibit 32

Certification Pursuant to 18 U.S.C. Section 1350

(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)

In connection with this quarterly report of Nanophase Technologies Corporation (the “Company”) on Form 10-Q for the quarter ending September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jess A. Jankowski, Chief Executive Officer, and acting as Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to our knowledge:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: November 16, 2020


	/s/ JESS A. JANKOWSKI
	Jess A. Jankowski
	Chief Executive Officer
	(principal executive officer, and principal financial officer)

EX-101.INS 5 nanx-20200930.xml XBRL INSTANCE DOCUMENT 0000883107 2020-01-01 2020-09-30 0000883107 2020-11-16 0000883107 nanx:PaycheckProtectionProgramMember 2020-09-30 0000883107 nanx:PaycheckProtectionProgramMember 2020-04-17 0000883107 nanx:PaycheckProtectionProgramMember 2020-04-16 2020-04-17 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-12-31 0000883107 nanx:TermLoanMember 2020-04-17 0000883107 nanx:TermLoanMember 2020-04-16 2020-04-17 0000883107 us-gaap:RevolvingCreditFacilityMember 2020-04-17 0000883107 nanx:JointDevelopmentAgreementMember nanx:SumitomoCorporationOfAmericasMember 2019-07-31 0000883107 nanx:JointDevelopmentAgreementMember nanx:SumitomoCorporationOfAmericasMember 2019-07-01 2019-07-31 0000883107 2020-09-30 0000883107 2019-12-31 0000883107 nanx:JointDevelopmentAgreementMember nanx:SumitomoCorporationOfAmericasMember 2020-01-01 2020-09-30 0000883107 nanx:JointDevelopmentAgreementMember nanx:SumitomoCorporationOfAmericasMember 2020-07-01 2020-09-30 0000883107 2019-07-01 2019-09-30 0000883107 2019-01-01 2019-09-30 0000883107 us-gaap:RevolvingCreditFacilityMember 2020-09-30 0000883107 nanx:BusinessLoanAgreementMember nanx:BeachcorpLLCMember 2020-09-08 0000883107 us-gaap:LetterOfCreditMember 2014-07-31 0000883107 us-gaap:LetterOfCreditMember 2014-07-01 2014-07-31 0000883107 nanx:FirstAmendmentTooOurMasterAgreementMember nanx:TermLoanAndTheRevolverFacilityMember nanx:BeachcorpLLCMember us-gaap:ExtendedMaturityMember 2020-03-22 2020-03-23 0000883107 nanx:BusinessLoanAgreementMember nanx:BeachcorpLLCMember 2018-11-16 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2018-11-16 0000883107 nanx:BusinessLoanAgreementMember nanx:BeachcorpLLCMember 2018-11-15 2018-11-16 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2018-11-15 2018-11-16 0000883107 nanx:BusinessLoanAgreementMember nanx:BeachcorpLLCMember 2020-09-30 0000883107 nanx:BusinessLoanAgreementMember nanx:BeachcorpLLCMember 2020-01-01 2020-09-30 0000883107 nanx:CreditFacilityMember 2020-01-01 2020-09-30 0000883107 nanx:CreditFacilityMember 2019-01-01 2019-12-31 0000883107 nanx:SecuredConvertiblePromissoryNoteMember nanx:BradfordTWhitmoreMember 2020-09-30 0000883107 nanx:SecuredConvertiblePromissoryNoteMember nanx:BradfordTWhitmoreMember 2019-12-31 0000883107 nanx:SecuredConvertiblePromissoryNoteMember nanx:BradfordTWhitmoreMember 2019-11-19 2019-11-20 0000883107 nanx:SecuredConvertiblePromissoryNoteMember nanx:BradfordTWhitmoreMember 2019-11-20 0000883107 us-gaap:LineOfCreditMember nanx:NewBusinessLoanAgreementMember us-gaap:IndividuallyImmaterialCounterpartiesMember 2019-03-21 2019-03-22 0000883107 us-gaap:LineOfCreditMember nanx:NewBusinessLoanAgreementMember us-gaap:IndividuallyImmaterialCounterpartiesMember 2019-03-22 0000883107 us-gaap:LineOfCreditMember nanx:NewBusinessLoanAgreementMember us-gaap:IndividuallyImmaterialCounterpartiesMember 2020-09-30 0000883107 us-gaap:LineOfCreditMember nanx:NewBusinessLoanAgreementMember us-gaap:IndividuallyImmaterialCounterpartiesMember 2020-03-30 0000883107 us-gaap:LineOfCreditMember nanx:NewBusinessLoanAgreementMember us-gaap:IndividuallyImmaterialCounterpartiesMember 2020-03-29 2020-03-30 0000883107 us-gaap:LineOfCreditMember nanx:NewBusinessLoanAgreementMember us-gaap:IndividuallyImmaterialCounterpartiesMember 2020-06-29 0000883107 us-gaap:LineOfCreditMember nanx:NewBusinessLoanAgreementMember us-gaap:IndividuallyImmaterialCounterpartiesMember 2020-06-28 2020-06-29 0000883107 us-gaap:LineOfCreditMember nanx:NewBusinessLoanAgreementMember us-gaap:IndividuallyImmaterialCounterpartiesMember 2019-12-31 0000883107 us-gaap:LineOfCreditMember nanx:NewBusinessLoanAgreementMember us-gaap:IndividuallyImmaterialCounterpartiesMember 2019-01-01 2019-12-31 0000883107 nanx:BusinessLoanAgreementMember nanx:BeachcorpLLCMember nanx:BradfordTWhitmoreMember 2020-09-30 0000883107 nanx:SecuredConvertiblePromissoryNoteMember nanx:BradfordTWhitmoreMember 2020-07-01 2020-09-30 0000883107 nanx:SecuredConvertiblePromissoryNoteMember nanx:BradfordTWhitmoreMember 2020-01-01 2020-09-30 0000883107 nanx:BusinessLoanAgreementMember nanx:BeachcorpLLCMember 2020-07-01 2020-09-30 0000883107 nanx:BusinessLoanAgreementMember nanx:BeachcorpLLCMember 2019-07-01 2019-09-30 0000883107 us-gaap:LineOfCreditMember nanx:NewBusinessLoanAgreementMember us-gaap:IndividuallyImmaterialCounterpartiesMember 2020-09-29 0000883107 us-gaap:LineOfCreditMember nanx:NewBusinessLoanAgreementMember us-gaap:IndividuallyImmaterialCounterpartiesMember 2020-09-28 2020-09-29 0000883107 2020-07-01 2020-09-30 0000883107 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000883107 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0000883107 us-gaap:EmployeeStockOptionMember 2020-09-30 0000883107 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0000883107 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0000883107 us-gaap:SupplyCommitmentMember 2020-09-30 0000883107 us-gaap:SupplyCommitmentMember srt:MinimumMember 2020-09-30 0000883107 us-gaap:SupplyCommitmentMember srt:MaximumMember 2020-01-01 2020-09-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerOneMember 2020-01-01 2020-09-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerTwoMember 2020-01-01 2020-09-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerThreeMember 2020-01-01 2020-09-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerFourMember 2020-01-01 2020-09-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerOneMember 2019-01-01 2019-09-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerTwoMember 2019-01-01 2019-09-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerThreeMember 2019-01-01 2019-09-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerFourMember 2019-01-01 2019-09-30 0000883107 nanx:CustomerOneMember 2020-09-30 0000883107 nanx:CustomerTwoMember 2020-09-30 0000883107 nanx:CustomerThreeMember 2020-09-30 0000883107 nanx:CustomerFourMember 2020-09-30 0000883107 2018-12-31 0000883107 2019-09-30 0000883107 nanx:CustomerOneMember 2019-09-30 0000883107 nanx:CustomerTwoMember 2019-09-30 0000883107 nanx:CustomerThreeMember 2019-09-30 0000883107 nanx:CustomerFourMember 2019-09-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerOneMember 2020-07-01 2020-09-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerTwoMember 2020-07-01 2020-09-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerThreeMember 2020-07-01 2020-09-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerFourMember 2020-07-01 2020-09-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerOneMember 2019-07-01 2019-09-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerTwoMember 2019-07-01 2019-09-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerThreeMember 2019-07-01 2019-09-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerFourMember 2019-07-01 2019-09-30 0000883107 us-gaap:ManufacturedProductOtherMember 2020-01-01 2020-09-30 0000883107 nanx:AdvancedMaterialsMember 2020-01-01 2020-09-30 0000883107 nanx:SolesenceMember 2020-01-01 2020-09-30 0000883107 us-gaap:ManufacturedProductOtherMember 2019-01-01 2019-09-30 0000883107 nanx:AdvancedMaterialsMember 2019-01-01 2019-09-30 0000883107 nanx:SolesenceMember 2019-01-01 2019-09-30 0000883107 us-gaap:ManufacturedProductOtherMember 2020-07-01 2020-09-30 0000883107 nanx:AdvancedMaterialsMember 2020-07-01 2020-09-30 0000883107 nanx:SolesenceMember 2020-07-01 2020-09-30 0000883107 us-gaap:ManufacturedProductOtherMember 2019-07-01 2019-09-30 0000883107 nanx:AdvancedMaterialsMember 2019-07-01 2019-09-30 0000883107 nanx:SolesenceMember 2019-07-01 2019-09-30 0000883107 us-gaap:NonUsMember 2020-07-01 2020-09-30 0000883107 us-gaap:NonUsMember 2020-01-01 2020-09-30 0000883107 us-gaap:NonUsMember 2019-07-01 2019-09-30 0000883107 us-gaap:NonUsMember 2019-01-01 2019-09-30 0000883107 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000883107 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000883107 us-gaap:CommonStockMember 2018-12-31 0000883107 us-gaap:CommonStockMember 2019-03-31 0000883107 us-gaap:CommonStockMember 2019-06-30 0000883107 us-gaap:CommonStockMember 2019-09-30 0000883107 us-gaap:CommonStockMember 2019-12-31 0000883107 us-gaap:CommonStockMember 2020-03-31 0000883107 us-gaap:CommonStockMember 2020-06-30 0000883107 us-gaap:CommonStockMember 2020-09-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000883107 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000883107 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000883107 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000883107 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000883107 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000883107 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000883107 us-gaap:RetainedEarningsMember 2018-12-31 0000883107 us-gaap:RetainedEarningsMember 2019-03-31 0000883107 us-gaap:RetainedEarningsMember 2019-06-30 0000883107 us-gaap:RetainedEarningsMember 2019-09-30 0000883107 us-gaap:RetainedEarningsMember 2019-12-31 0000883107 us-gaap:RetainedEarningsMember 2020-03-31 0000883107 us-gaap:RetainedEarningsMember 2020-06-30 0000883107 us-gaap:RetainedEarningsMember 2020-09-30 0000883107 2019-01-01 2019-03-31 0000883107 2019-04-01 2019-06-30 0000883107 2020-01-01 2020-03-31 0000883107 2020-04-01 2020-06-30 0000883107 2019-03-31 0000883107 2019-06-30 0000883107 2020-03-31 0000883107 2020-06-30 0000883107 us-gaap:ProductMember 2020-07-01 2020-09-30 0000883107 us-gaap:ProductMember 2019-07-01 2019-09-30 0000883107 us-gaap:ProductAndServiceOtherMember 2020-07-01 2020-09-30 0000883107 us-gaap:ProductAndServiceOtherMember 2019-07-01 2019-09-30 0000883107 us-gaap:ProductMember 2020-01-01 2020-09-30 0000883107 us-gaap:ProductMember 2019-01-01 2019-09-30 0000883107 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-09-30 0000883107 us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-09-30 0000883107 us-gaap:EmployeeStockOptionMember 2019-09-30 0000883107 nanx:JointDevelopmentAgreementMember nanx:SumitomoCorporationOfAmericasMember 2019-08-01 2020-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure nanx:Number NANOPHASE TECHNOLOGIES Corp 0000883107 10-Q false 2020-09-30 000-22333 DE --12-31 Yes Yes true Non-accelerated Filer false false 38215792 Q3 2020

0.63

0.20

0.32

0.13

0.14

0.04

0.64

0.00

0.09

0.30

0.18

0.16

0.00

0.75

0.00

0.04

952000

500000

2000000

500000

2021-03-31

2020-12-31

2024-05-15

PPP note in eighteen equal monthly installments, with the first payment being due on a date yet to be determined. The Company is in the process of applying for loan forgiveness and does not expect resolution until the first quarter of 2021.

309000 575000 P10Y

12262000

229000

47000

3069000

10118000

3888000

4190000

3678000

4394000

6464000

1988000

1666000

753000

1582000

1553000

2304000

388000

377000

3827000

3043000

61000

26000

11929000

9797000

333000

321000

250000

30000

0.01

0.03

0.01

Prime rate

2750000

500000

2000000

500000

734000

500000

2020-04-02 2020-07-01 2020-01-02 2020-10-02 0.75 2

500000

2021-07-01

2020-03-31

2021-04-20

0.0100

0.0825

0.02

0.63

Secured by all the unencumbered assets of the Company

2000000

0.20

0.32

1103000 1170000 1200000

1030000

830000

368000

47000

140000

122000

27000

10000

12000

9000

2187000

1425000

1427000

1170000

3614000

2595000

30000

41000

3584000

2554000

54000

18000

52000

17000

30000

14000

44000

9000

84000 32000 96000 26000

425000

129000

375000

140000

81000

27000

81000

27000

12000

16000

68000

10000

518000

172000

524000

177000

602000

204000

620000

203000

518000

509000

P1Y10M25D

P2Y2M12D

P3Y4M24D

P3Y3M19D

0.093

.091

0.143

.144

172000

701000

720000

705000

595000

1000

2894000

717000

2177000

63000

196000

109000

5000

373000

39000

334000

235000 897000 829000 710000 595000 1000 3267000 756000 2511000

1917000

2119000

411000

357000

1766000

2035000

0.0050

0.0230

0.0000

P7Y

0.94

0.36

0.41

147000

179000

48000

64000

290000

P1Y9M18D

535000

547500

78277

36000

78277

23000

16000

1000

16000

22000

16000

460640

130500

202134

48600

3507073

3747400

0.58

0.64

4 4

2451000

970000

901000

328000

291000

420000

1042000

122000

0 1000000 500000 500000 1000000 0.30 1.15

1242000

2747000

33000

734000

1134000

1194000

599000

267000

7768000

4985000

2650000

2255000

11000

13000

12346000

9372000

500000

1541000

224000

500000

186000

218000

1668000

1748000

309000

482000

647000

380000

5762000

4409000

148000

288000

1030000

830000

952000

93000

212000

206000

4108000

3452000

382000

381000

102055000

101886000

-99961000

-100756000

2476000

1511000

1384000

1233000

339000

381000

382000

98795000

98852000

100560000

100624000

101886000

101938000

101985000

102055000

-97750000

-98263000

-98910000

-99772000

-100756000

-100923000

-100391000

-99961000

928000

2031000

1396000

1975000

12346000

9372000

9000

0.01

24088

0.01

55000000

38215069

38136792

38215069

38136792

7832000

2506000

7839000

2201000

4430000

563000

2279000

1687000

1134000

488000

1450000

405000

2133000

890000

2711000

730000

1163000

-815000

-1882000

552000

795000

-862000

-2022000

430000

795000

-862000

-2022000

430000

-513000

-647000

-862000

-167000

532000

430000

-513000

-647000

-167000

532000

0.02

-0.02

-0.06

0.01

38138453

38136792

36077257

38141741

0.02

-0.02

-0.06

0.01

38228453

38136792

36077257

38432741

33911792

38136792

38215069

64000

48000

57000

58000

64000

52000

47000

48000

57000

58000

52000

47000

265000

234000

-16000

147000

179000

200000

1481000

544000

1030000

-98000

332000

12000

-284000

-632000

267000

-19000

-266000

594000

13000

53000

-1732000

-2161000

448000

523000

-448000

-523000

172000

162000

1500000

1000000

1500000

500000

10390000

8166000

9073000

7895000

952000

1676000

23000

16000

2120000

2301000

-60000

-383000

1134000

1194000

1345000

962000

152000

126000

204000

18000

(1) Basis of Presentation   The accompanying unaudited consolidated condensed interim financial statements of Nanophase Technologies Corporation (“Nanophase”, “Company”, “we”, “our”, or “us”) reflect all adjustments (consisting of normal recurring adjustments) which, in the opinion of management, are necessary for a fair presentation of our financial position and operating results for the interim periods presented. All statements include the results from both Nanophase and our wholly owned subsidiary, Solésence, LLC (“Solésence®,” or our “Solésence® subsidiary”). Operating results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020.   These financial statements should be read in conjunction with our audited financial statements and notes thereto for the year ended December 31, 2019, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission.

(2)         Going Concern / Liquidity   We believe that cash from operations and cash on hand, in addition to unused borrowing capacity, may not be adequate to fund our operating plans through September 30, 2021. We are working to reduce these risks, but some of this is dependent on several things, some of which we have limited control. Our largest customer made up 63% of our 2019 revenue and has seen a significant reduction in orders placed to us in 2020. We have also seen a rapid increase in sales of our Solésence® products, adding working capital pressure in terms of additional inventory and accounts receivable. Both of these issues have limited our flexibility and required us to make cash management a top priority. After April 17, 2020, some of this pressure was mitigated due to our receipt of a $952 loan under the Paycheck Protection Program (the “PPP”), as discussed more fully below. We also have a $500 term loan, and revolving credit facility with a maximum credit limit of $2,750, both described more fully below, with principal due on March 31, 2021. In the event that we are unable to either extend the maturity, or potentially refinance this loan, we may have difficulty funding ongoing operations. Notwithstanding the fact that visibility into the ongoing impact of the various reactions and policies relating to, the Covid-19 pandemic is limited, it is currently management’s belief that we will continue to achieve strong growth in Solésence® sales through 2020. Given these issues, and other commercial realities, we are monitoring the additional working capital demands that this could create as we continue to execute on our Solésence® growth strategy. It is also management’s belief that the Covid-19 pandemic, related governmental reaction, and resulting economic slow-down has, and is expected to continue, to affect certain consumer behaviors and markets has had a negative impact on its Personal Care Ingredients customers during 2020, with a current lack of visibility as to how far this impact may extend in to 2021. Management believes the outlook after the fourth quarter is uncertain, but a continuation of the Covid-19 pandemic and related reactions and policies going forward would be expected to maintain a degree of negative impact on the Company and its businesses. While customer demand over the next several months is currently known, Management believes the negative impacts late in the fourth quarter and, if applicable, thereafter, are not currently quantifiable. The timing of cash flows is critical. If cash generated from operations is not materially consistent with our plans, we believe that we may need to seek additional funding to address working capital demands. The trading volume of our stock has been low enough that we expect it would be difficult to sell enough shares, assuming our shareholders would approve the authorization of additional shares, to generate additional capital via the OTC market. These uncertainties have caused us to be unable to assert that, for the next twelve months, we have enough current cash, guaranteed access to financing to fund operations, or access to cash in the equity markets to continue with our current growth strategy in terms of investment in capital equipment and in operating expenses related to Solésence®.   On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (SARS-CoV-2) to be a global pandemic (COVID-19), which continues to spread throughout the United States and around the world. On April 23, 2020, the Governor of the State of Illinois extended his order that all non-essential businesses cease all activities within the State of Illinois except for certain minimum basic operations through May 30, 2020, and such executive order has been temporarily lifted. Given the uncertain progress toward combatting the SARS-CoV-2 virus, we expect there to be further disruptions in the local, national, and global economies. During these disruptions, we are doing everything we can to allow as many of our employees as possible to shelter-in-place. Relative to any further executive orders in Illinois, management believes that Nanophase Technologies and its Solésence® subsidiary qualify as essential businesses as defined, due to our product offerings supporting healthcare, and critical manufacturing and chemical products within sectors that have been designated as critical infrastructure, the continued operation of which is vital for national public health, economic security, and safety.   The Company believes that its customers and suppliers may have similar disruptions, which may lead to greater reductions in their normal operations as a result of responses to the coronavirus pandemic in Illinois and in other jurisdictions in the United States and worldwide.  Currently, the Company is consequently aware of changes in its business as a result of the coronavirus pandemic, but uncertain of the impacts of those changes on its consolidated statements of position, operations or cash flows.  As of the date of this filing, we are reasonably confident in customer demand through 2020 and in to the first quarter of 2021. Demand for the second quarter of 2021, and the subsequent quarter, is not yet clear to management. We believe the resulting cessations, reductions, and disruptions in its customers’ and suppliers’ operations could be temporary; however, the Company’s management also believes the duration and, hence, the potential impact of such cessations, reductions, and disruptions is currently unknowable.  As a result, although we believe we have acceptable visibility through the first quarter of 2021, conditions are fluid and our estimates regarding the first quarter and beyond could prove inaccurate. Moreover, we are unable to clearly estimate the potential impact on our business for the balance of the year as of the date of this filing.   These circumstances raise significant doubt as to the Company’s ability to operate as a going concern under U.S. GAAP. The accompanying financial statements have been prepared on a going concern basis in accordance with U.S. GAAP. As such, no adjustments have been made to the unaudited condensed consolidated financial statements for the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue operating as a going concern.   On April 17, 2020, the Company received funding in the form of a loan under the “PPP,” under Division A, Title I of Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), in the amount of $952 which helped us to continue to pay our people, rent and utilities during the second quarter. Under the PPP, the Company may apply for forgiveness of the amount due on the loan in an amount equal to the sum of the following costs incurred during the 24-week period beginning on the date of the first disbursement of the Loan: (a) payroll costs, (b) any payment of interest on a covered obligation (which shall not include any prepayment of or payment of principal on a covered mortgage obligation), (c) any payment on a covered rent obligation, and (d) any covered utility payment, calculated in accordance with the terms of the CARES Act. No assurance can be provided that the Company will obtain forgiveness of the Loan in whole or in part. The principal amount of the PPP note accrues interest at the rate of 1.00% per year. The Company will be required to pay any unforgiven principle and interest under the PPP note in eighteen equal monthly installments, with the first payment being due on a date yet to be determined. The Company is in the process of applying for loan forgiveness and does not expect resolution until the first quarter of 2021.

(3) Description of Business   Nanophase Technologies Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”) is a scientifically-driven company which, along with its wholly-owned subsidiary, Solésence, LLC (our “Solésence® subsidiary”), is focused in various beauty- and life-science markets. Skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy. We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in material engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of markets in skin care, including for use in sunscreens as active ingredients and as fully developed prestige skin care products, marketed and sold through our Solésence® subsidiary. In terms of our life sciences focus, we have seen current conditions significantly increase demand for our medical diagnostics ingredients, as testing for various viruses, most notably Covd-19, has become a critical use of our technology. Additionally, we continue to sell products in markets for architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications— all of which, along with medical diagnostics, fall into the advanced materials product category.    We target markets, primarily related to skin health products and ingredients, and diagnostic life sciences ingredients where we believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with current customers in these target markets to identify their material and performance requirements and market our materials to various end-use applications manufacturers, and our Solésence® products to cosmetics and skin care brands. Over the past few years, we have expanded our marketing efforts for our Solésence products and are seeing more customers responding to our successful products being sold into their markets. Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Active Stress Defense ™ Technology — which became the cornerstone of our new product development in personal care, with first revenue recognized during 2016. In addition, through the creation of our Solésence® subsidiary, we utilize this particle surface treatment to manufacture and sell fully developed solutions to targeted customers in the skin care industry, in addition to the ingredients we have traditionally sold in the personal care area.   Although our primary strategic focus has been the North American market, we currently sell material to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX.   While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products.

(4) Revenues   Revenues are recognized at a point in time, typically when control of the promised goods is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods.   Deferred revenue includes customer deposits and other receipts that are recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in the Company’s Consolidated Condensed Statement of Operations. Customer deposits, $309 as of September 30, 2020, have been classified as deferred revenue. At December 31, 2019, customer deposits amounted to $575.   On July 31, 2019, we entered into a Joint Development Agreement (“JDA”), with an initial term of ten years, with Sumitomo Corporation of Americas (“SCOA”) to jointly develop certain coated materials for the use in the personal care market. In return for the Company’s exclusive efforts on SCOA’s behalf, SCOA has paid a commitment fee of $250 and will pay two subsequent payments, of $125 each, for the development of products. The two subsequent payments are contingent upon the achievement of certain performance obligations as defined in the agreement. We began recognizing revenue from the commitment fee in November 2019 and will continue to do so as we fulfill our contractual performance obligations. In the case of the SCOA JDA, the Company is recognizing revenue over time using an input method. If the Company elects to terminate the agreement within the terms allowed and prior to achieving the initial performance obligations, the original $250 must be refunded.   As of September 30, 2020, the Company has recognized $250 in cumulative revenue from the SCOA JDA, of which $47 and $229 was recognized in the three and nine months ended September, 30 of 2020. The Company has recognized this revenue proportionally, based upon its estimate of the period over which the performance obligation is expected to be completed.

(6) Financial Instruments   We follow the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.   Our financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, along with the promissory note with no related borrowings described in Note 7, and any borrowings on the working capital line of credit from Libertyville Bank and Trust and any borrowings under the Master Agreement from Beachcorp, LLC described below in Note 7. The fair values of all financial instruments were not materially different from their carrying values. There were no financial assets or liabilities adjusted to fair value on September 30, 2020 or December 31, 2019.

(7) Notes and Line of Credit   During July 2014 we entered into a bank-issued letter of credit and related promissory note for up to $30 in borrowings to support our obligations under our facility lease agreement. No borrowings have been incurred under this promissory note. Should any borrowings occur in the future, the interest rate would be the prime rate plus 1%, with the bank having the right to “set off” or apply unpaid balances against our checking account if we fail to meet our obligations under any borrowings under the note. It is our intention to renew this note annually, for as long as we need to do so pursuant to the terms of our facility lease agreement. This note was renewed through July 1, 2021. Because there were no amounts outstanding on the note at any time during 2020 or 2019, we have recorded no related liability on our balance sheet.   On March 22, 2019, we executed a Business Loan Agreement, dated as of March 4, 2019 (the “Loan Agreement”), with Libertyville Bank and Trust Company, a Wintrust Community Bank (“Libertyville”), our primary bank, the maturity of which was extended until April 20, 2021 pursuant to an amended and restated Promissory Note executed on June 25, 2020, and dated as of April 4, 2020. Under the Loan Agreement, Libertyville will provided a maximum of (i) $500 or (ii) two times the sum of (a) 75% our eligible accounts receivables and (b) our cash deposited with Libertyville, whichever is less, of revolving credit to us, collateralized by a senior priority lien on our accounts receivable, inventory, equipment, general intangibles and fixtures. Interest was payable monthly on any advances at a floating interest rate of the prime rate at the time plus 1%. We are required to have $500 in cash, inclusive of the borrowed amount, at Libertyville on the date of any advance. Advances could only occur at the beginning or end of a fiscal quarter and were required to be repaid in full within five business days of the advance. We borrowed $500 on September 29, 2020 and repaid it on October 2, 2020. We borrowed $500 on June 29, 2020 and repaid it on July 1, 2020. We borrowed $500 on March 30, 2020 and repaid it on April 2, 2020. We borrowed $500 on December 31, 2019 and repaid it on January 2, 2020.   On November 16, 2018, we entered into a Business Loan Agreement (the “Master Agreement”) with Beachcorp, LLC. Beachcorp, LLC is managed by Bradford T. Whitmore, who, together with his affiliates Grace Brothers, Ltd. and Grace Investments, Ltd., beneficially owned approximately 63% of the outstanding shares of our common stock as of September 30, 2020. The Master Agreement relates to two loan facilities, each evidenced by separate promissory notes, each dated November 16, 2018: a term loan to the Company of up to $500 to be disbursed in a single advance (the “Term Loan”) with a fixed annual interest rate of 8.25%, payable quarterly, accruing from the date of such advance and with principal due on December 31, 2020; and an asset-based revolving loan facility for the Company of up to $2,000 (the “Revolver Facility”), with floating interest accruing at the prime rate plus 3% (8.25% minimum) per year, with a borrowing base consisting of qualified accounts receivable of the Company, and with all principal and accrued interest initially to be due March 31, 2020. On March 23, 2020, the Company and Beachcorp, LLC executed the First Amendment to our Master Agreement that extends the maturities of both the Term Loan and the Revolver Facility to March 31, 2021. On September 8, 2020, the Company executed an updated Promissory Note to, and a Second Amendment to the Business Loan Agreement with Beachcorp, LLC, expanding the capacity of the Revolver Facility from $2,000 to $2,750. The Term Loan and Revolver Facility are secured by all the unencumbered assets of the Company and subordinated to Libertyville’s secured interest under the New Business Loan Agreement. The Master Agreement substantially restricts the Company’s ability to incur additional indebtedness during the terms of both the Term Loan and the Revolver Facility. On September 30, 2020, the balance on the term loan was $500 and the balance on the Revolver Facility was $1,541. There was $34 in related interest expense during the quarter ended September 30, 2020, of which $12 was accrued and $22 paid by the end of the quarter. There was $47 in related interest expense during the quarter ended September 30, 2019, of which $9 was accrued and $18 paid by the end of the quarter. As Beachcorp, LLC is an affiliate of Mr. Whitmore, this amounts to interest to be paid to a related party. On September 30, 2020, the Company had $734 in excess borrowing capacity over the $1,541 balance on the Revolver Facility. The balance of borrowing base, loan amount, and any excess payments required over the available borrowing base will change as frequently as daily, given the operational nature of the elements of the Revolver Facility.   On November 20, 2019, we entered into a 2% Secured Convertible Promissory Note with Bradford T. Whitmore in the principal amount of $2,000 (the “Convertible Note”). The principal amount is payable in a single payment on May 15, 2024 (the “Maturity Date”). The principal amount of the Convertible Note accrues interest at the rate of 2.0% per year, which interest is payable semi-annually on the 15th day of May and November, commencing on May 15, 2020. The principal amount and, at the holder’s option, accrued interest under the Convertible Note is convertible at the holder’s option into additional shares of the Company’s common stock in whole or in part and from time to time up to the Maturity Date at a conversion price of $0.20 per share. The convertible note contains a beneficial conversion feature since the Company’s stock was trading at $0.32 per share on the date the Company entered into the agreement. The intrinsic value of the beneficial conversion feature was $1.2 million on November 20, 2019 and is recorded as a discount on the convertible note. The discount will be accreted to the convertible note over the life of the note using the straight-line method. The offset to these discounts will be interest expense. For the three and nine months ended September 30, 2020, the Company accreted $67 and $200, respectively. The balance on the convertible note was $1,030 and $830, net of discounts of $1,103 and $1,170 at September 30, 2020 and December 31, 2019, respectively.   On September 30, 2020, the balance on the term loan was $500, the balance on the Revolver Facility was $1,541, the balance on the Convertible Note was $2,000. In the nine months ended September 30, 2020, there was $334 in interest expense relating to these credit facilities held by Beachcorp, LLC. The accrued interest expense balance on these related party credit facilities amounted to $27, and $10, at September 30, 2020 and December 31, 2019, respectively. The obligations under the Convertible Note are secured by a security interest in all of the Company’s personal property pursuant to a Commercial Security Agreement among Mr. Whitmore, the Company and Solésence, LLC, the Company’s sole subsidiary. Given that Beachcorp, LLC is an affiliate of Mr. Whitmore, this amounts to all of this interest being owed to a related party.   On April 17, 2020, we entered into a Promissory Note, dated as of April 16, 2020, in favor of Libertyville in the principal amount of $952 for our loan under the PPP. The Company may apply for forgiveness of the amount due on the loan in an amount equal to the sum of the following costs incurred during the 24-week period beginning on the date of the first disbursement of the Loan: (a) payroll costs, (b) any payment of interest on a covered obligation (which shall not include any prepayment of or payment of principal on a covered mortgage obligation), (c) any payment on a covered rent obligation, and (d) any covered utility payment, calculated in accordance with the terms of the CARES Act. No assurance can be provided that the Company will obtain forgiveness of the Loan in whole or in part. The principal amount of the PPP note accrues interest at the rate of 1.00% per year. The Company will be required to pay any unforgiven principle and interest under the PPP note in eighteen equal monthly installments, with the first payment being due on November 17, 2020 and continuing on the same day of each subsequent month until April 17, 2022. On September 30, 2020, the balance under the PPP note was $952.

(8) Inventories   Inventories consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td style="font-weight: bold; line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; font-weight: bold; line-height: normal; text-align: center; font-size-adjust: none; font-stretch: normal">September 30, 2020</td> <td style="font-weight: bold; line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; line-height: normal; text-align: center; font-size-adjust: none; font-stretch: normal">December 31, 2019</td> <td style="line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="2" style="line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="2" style="line-height: normal; text-align: center; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="line-height: normal; width: 74%; text-align: left; font-size-adjust: none; font-stretch: normal">Raw materials</td> <td style="line-height: normal; width: 1%; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; width: 10%; text-align: right; font-size-adjust: none; font-stretch: normal">2,187</td> <td style="line-height: normal; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; width: 10%; text-align: right; font-size-adjust: none; font-stretch: normal">1,425</td> <td style="line-height: normal; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: normal; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal">Finished goods</td> <td style="line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">1,427</td> <td style="line-height: normal; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">1,170</td> <td style="line-height: normal; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">3,614</td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">2,595</td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: normal; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal">Allowance for excess inventory quantities</td> <td style="line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">(30</td> <td style="line-height: normal; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal">)</td> <td style="line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">(41</td> <td style="line-height: normal; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="line-height: normal; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal">$</td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">3,584</td> <td style="line-height: normal; text-align: left; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal">$</td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">2,554</td> <td style="line-height: normal; text-align: left; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td></tr> </table>

(11) Significant Customers and Contingencies   Revenue from four customers constituted approximately 30%, 18%, 16% and 16%, respectively, of our total revenue for the three months ended September 30, 2020. For the nine months ended September 30, 2020, revenue from the same four customers was approximately 20%, 32%, 13% and 14%, respectively. Amounts included in accounts receivable on September 30, 2020 relating to these four customers were approximately $901, $328, $291 and $420, respectively. Revenue from these four customers constituted approximately 0%, 75%, 0% and 4%, respectively, for the three months ended September 30, 2019. For the nine months ended September 30, 2019, revenue from the same four customers was approximately 4%, 64%, 0%, and 9%, respectively. Amounts included in accounts receivable on September 30, 2019 relating to these four customers were approximately $0, $1,042, $0 and $122, respectively. The loss of one of these significant customers, a significant decrease in revenue from one or more of these customers, or the failure to attract new customers could have a material adverse effect on our business, results of operations and financial condition.   We currently have exclusive supply agreements with BASF Corporation (“BASF”), our largest customer, that have contingencies outlined which could potentially result in the license of technology and/or the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements, certain other obligations and/or certain financial condition covenants. The financial condition covenants in one of our supply agreements with BASF “trigger” a technology transfer right (license and equipment sale at BASF’s option) in the event (a) that earnings for the twelve-month period ending with our most recently published quarterly financial statements are less than zero and a minimum of $1 million in total of certain assets of which at least $500 must be in cash, cash equivalents and certain investments, with the balance being composed of certain inventory and receivables, is not maintained or (b) of an acceleration of any debt maturity having a principal amount of more than $10 million. There are certain minimum finished goods inventory requirements with the 2019 amendment to the supply agreement. This agreement also requires Nanophase to maintain certain finished goods inventory levels as “safety stock,” beginning in the first quarter of 2019, and increasing through the third quarter of 2019 to a negotiated level based on agreed demand metrics, in order to maintain the $500 non-cash component discussed above. After September 30, 2019, should our safety stock fall below the prescribed amount of material, the quarter-end cash requirement would revert to $1,000 in cash, cash equivalents, and certain investments. The safety stock requirement may be adjusted upon mutual agreement.   Our supply agreements with BASF also “trigger” a technology transfer right in the event of our insolvency, as further defined within the agreements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either 115% of the equipment’s net book value or the greater of 30% of the original book value of such equipment, and any associated upgrades to it, or 115% of the equipment’s net book value, depending on the equipment and related products.   We expect to expend resources on research, development and product testing, and in expanding current capacity or capability for new business. In addition, we may incur significant costs in preparing, filing, prosecuting, maintaining and enforcing our patents and other proprietary rights. We may need additional financing if we were to lose an existing customer or suffer a significant decrease in revenue from one or more of our customers or because of currently unknown capital requirements, new regulatory requirements or the need to meet the cash requirements discussed above to avoid a triggering event under our BASF agreement. Given our expected growth in our Solésence® business, we may also have temporary working capital demands that we cannot fund with existing capital, while remaining in compliance with the covenants included in our BASF agreement described above. If necessary, we may seek funding through public or private financing and through contracts with governmental entities or other companies. Additional financing may not be available on acceptable terms or at all, and any such additional financing could be dilutive to our shareholders. If we are unable to obtain adequate funds, we may be required to delay, scale-back or eliminate some of our manufacturing and marketing operations or we may need to obtain funds through arrangements on less favorable terms. Such circumstances could raise doubt as to our ability to continue as a going concern. If we obtain funding on unfavorable terms, we may be required to relinquish rights to some of our intellectual property.

(12) Business Segmentation and Geographical Distribution   Revenue from international sources approximated $1,242 and $2,747 for the three and nine months ended September 30, 2020, respectively, compared to $33 and $734 for the three and nine months ended September 30, 2019, respectively. All of this revenue was product revenue.   Our operations comprise a single business segment and all our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence®. The revenues for the three months and nine months ended September 30, 2020 and 2019, by category, are as follows:   <table align="center" cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td> <td style="font-weight: bold; line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="6" style="border-bottom: black 1pt solid; font-weight: bold; line-height: normal; text-align: center; font-size-adjust: none; font-stretch: normal">For the three months ended September 30,</td> <td style="font-weight: bold; line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="font-weight: bold; line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="6" style="border-bottom: black 1pt solid; font-weight: bold; line-height: normal; text-align: center; font-size-adjust: none; font-stretch: normal">For the nine months ended September 30,</td> <td style="font-weight: bold; line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font-weight: bold; line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal">Product Category</td> <td style="font-weight: bold; line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; line-height: normal; text-align: center; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">2020</td> <td style="font-weight: bold; line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="font-weight: bold; line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; line-height: normal; text-align: center; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">2019</td> <td style="font-weight: bold; line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="font-weight: bold; line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; line-height: normal; text-align: center; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">2020</td> <td style="font-weight: bold; line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="font-weight: bold; line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; line-height: normal; text-align: center; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">2019</td> <td style="font-weight: bold; line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="line-height: normal; width: 48%; text-align: left; font-size-adjust: none; font-stretch: normal">Personal Care Ingredients</td> <td style="line-height: normal; width: 1%; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; width: 10%; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">753</td> <td style="line-height: normal; width: 1%; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; width: 10%; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">2,304</td> <td style="line-height: normal; width: 1%; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; width: 10%; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">4,190</td> <td style="line-height: normal; width: 1%; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; width: 10%; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">6,464</td> <td style="line-height: normal; width: 1%; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal">Advanced Materials</td> <td style="line-height: normal; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">1,582</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">388</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">3,678</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">1,988</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="line-height: normal; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal">Solésence®</td> <td style="line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">1,553</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">377</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">4,394</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">1,666</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: normal; text-align: left; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal">Total Sales</td> <td style="line-height: normal; color: rgb(0, 0, 0); padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">$</td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">3,888</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; color: rgb(0, 0, 0); padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">$</td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">3,069</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; color: rgb(0, 0, 0); padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">$</td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">12,262</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; color: rgb(0, 0, 0); padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">$</td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">10,118</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td></tr> </table>

Inventories consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td style="font-weight: bold; line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; font-weight: bold; line-height: normal; text-align: center; font-size-adjust: none; font-stretch: normal">September 30, 2020</td> <td style="font-weight: bold; line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; line-height: normal; text-align: center; font-size-adjust: none; font-stretch: normal">December 31, 2019</td> <td style="line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="2" style="line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="2" style="line-height: normal; text-align: center; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="line-height: normal; width: 74%; text-align: left; font-size-adjust: none; font-stretch: normal">Raw materials</td> <td style="line-height: normal; width: 1%; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; width: 10%; text-align: right; font-size-adjust: none; font-stretch: normal">2,187</td> <td style="line-height: normal; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; width: 10%; text-align: right; font-size-adjust: none; font-stretch: normal">1,425</td> <td style="line-height: normal; width: 1%; text-align: left; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: normal; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal">Finished goods</td> <td style="line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">1,427</td> <td style="line-height: normal; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">1,170</td> <td style="line-height: normal; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">3,614</td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">2,595</td> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: normal; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal">Allowance for excess inventory quantities</td> <td style="line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">(30</td> <td style="line-height: normal; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal">)</td> <td style="line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">(41</td> <td style="line-height: normal; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="line-height: normal; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal">$</td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">3,584</td> <td style="line-height: normal; text-align: left; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal">$</td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: right; font-size-adjust: none; font-stretch: normal">2,554</td> <td style="line-height: normal; text-align: left; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td></tr></table>

The revenues for the three months and nine months ended September 30, 2020 and 2019, by category, are as follows:   <table align="center" cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td> <td style="font-weight: bold; line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="6" style="border-bottom: black 1pt solid; white-space: nowrap; font-weight: bold; line-height: normal; text-align: center; font-size-adjust: none; font-stretch: normal">For the three months ended September 30,</td> <td style="font-weight: bold; line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="font-weight: bold; line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="6" style="border-bottom: black 1pt solid; white-space: nowrap; font-weight: bold; line-height: normal; text-align: center; font-size-adjust: none; font-stretch: normal">For the nine months ended September 30,</td> <td style="font-weight: bold; line-height: normal; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font-weight: bold; line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal">Product Category</td> <td style="font-weight: bold; line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; line-height: normal; text-align: center; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">2020</td> <td style="font-weight: bold; line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="font-weight: bold; line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; line-height: normal; text-align: center; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">2019</td> <td style="font-weight: bold; line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="font-weight: bold; line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; line-height: normal; text-align: center; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">2020</td> <td style="font-weight: bold; line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="font-weight: bold; line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; line-height: normal; text-align: center; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">2019</td> <td style="font-weight: bold; line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="line-height: normal; width: 48%; text-align: left; font-size-adjust: none; font-stretch: normal">Personal Care Ingredients</td> <td style="line-height: normal; width: 1%; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; width: 10%; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">753</td> <td style="line-height: normal; width: 1%; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; width: 10%; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">2,304</td> <td style="line-height: normal; width: 1%; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; width: 10%; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">4,190</td> <td style="line-height: normal; width: 1%; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; width: 1%; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">$</td> <td style="line-height: normal; width: 10%; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">6,464</td> <td style="line-height: normal; width: 1%; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: normal; text-align: left; font-size-adjust: none; font-stretch: normal">Advanced Materials</td> <td style="line-height: normal; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">1,582</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">388</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">3,678</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">1,988</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="line-height: normal; text-align: left; padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal">Solésence®</td> <td style="line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">1,553</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">377</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">4,394</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 1pt solid; line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">1,666</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); padding-bottom: 1pt; font-size-adjust: none; font-stretch: normal"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: normal; text-align: left; padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal">Total Sales</td> <td style="line-height: normal; color: rgb(0, 0, 0); padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">$</td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">3,888</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; color: rgb(0, 0, 0); padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">$</td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">3,069</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; color: rgb(0, 0, 0); padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">$</td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">12,262</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="line-height: normal; color: rgb(0, 0, 0); padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: left; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">$</td> <td style="border-bottom: black 2.5pt double; line-height: normal; text-align: right; color: rgb(0, 0, 0); font-size-adjust: none; font-stretch: normal">10,118</td> <td style="line-height: normal; text-align: left; color: rgb(0, 0, 0); padding-bottom: 2.5pt; font-size-adjust: none; font-stretch: normal"> </td></tr></table>

(5) Earnings Per Share    Options to purchase approximately 165,000 and 497,000 shares of common stock that were outstanding as of September 30, 2019 were not included in the computation of loss per share for the three and nine months ended September 30, 2019, respectively, as the impact of such shares would be anti-dilutive.

42000

1634000

1676000

4189000

(9) Leases   The Company's operating lease portfolio is comprised of operating leases for office, warehouse space and equipment. Certain of the Company's leases include one or more options to renew or terminate the lease at the Company's discretion. The Company regularly evaluates the renewal and termination options and when they are reasonably certain of exercise, includes the renewal or termination option in our lease term.    As of September 30, 2020, the operating lease right-of-use “ROU” asset had a balance of $1,917 which is included in the “Operating lease right-of-use assets” line item of these condensed consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $411 and $1,766 respectively. As of December 31, 2019, the ROU asset had a balance of $2,119 which is included in the “Operating lease right-of-use assets” line item of these condensed consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $357 and $2,035 respectively. These are included in the “Current portion of operating lease obligations” and “Long-term operating lease obligations, net of current portion” line items of these condensed consolidated financial statements. The discount rates used for leases accounted for under ASC 842 are based on an interest rate yield curve developed for the leases in the Company’s portfolio.   The office leases contain variable lease payments which consist primarily of rent escalations based on an established index or rate and taxes, insurance, and common area or other maintenance costs, which are paid based on actual costs incurred by the lessor.   Quantitative information regarding the Company’s leases is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended September 30,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Nine Months Ended September 30,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2019</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2019</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Components of lease cost</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Finance lease cost components:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 41%; text-align: left"> Amortization of finance lease assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; color: #000000; text-align: right">17</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; color: #000000; text-align: right">18</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; color: #000000; text-align: right">54</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; color: #000000; text-align: right">52</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">      Interest on finance lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">9</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">14</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">30</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">44</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">     Total finance lease costs</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">26</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">32</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">84</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">96</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating lease cost components:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">    Operating lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">140</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">129</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">425</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">375</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">    Variable lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">27</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">27</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">81</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">81</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">    Short-term lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">10</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">16</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">68</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">      Total operating lease costs</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">177</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">172</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">518</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">524</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> Total lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">203</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">204</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">602</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">620</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: #000000; text-align: left"> </td></tr> </table>   Supplemental cash flow information related to leases is as follows for the nine months ended:   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%"> <tr style="font-size: 10pt; vertical-align: bottom"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt">September 30, 2020</td> <td style="font-size: 10pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">September 30, 2019</td></tr> <tr style="font-size: 10pt; vertical-align: bottom"> <td style="font-size: 10pt; text-align: left">Cash paid for amounts included in the measurement of liabilities:</td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="text-align: right; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td></tr> <tr style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">           Operating cash outflow from operating leases</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; color: #000000; text-align: right">518</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left"> </td> <td style="font-size: 10pt; width: 2%"> </td> <td style="font-size: 10pt; width: 1%">$</td> <td style="text-align: right; font-size: 10pt; width: 9%">509</td> <td style="font-size: 10pt; width: 1%"> </td></tr> <tr style="font-size: 10pt; vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Right-of-use assets obtained in exchange for lease obligations: </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="text-align: right; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td></tr> <tr style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">           Operating leases </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">—</td><td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt">$</td> <td style="text-align: right; font-size: 10pt">205</td> <td style="font-size: 10pt"> </td></tr> <tr style="font-size: 10pt; vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"> Weighted-average remaining lease term-finance leases (in years)</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">1.9</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="text-align: right; font-size: 10pt">2.2</td> <td style="font-size: 10pt"> </td></tr> <tr style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left"> Weighted-average remaining lease term-operating leases (in years)</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">3.4</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="text-align: right; font-size: 10pt">3.3</td> <td style="font-size: 10pt"> </td></tr> <tr style="font-size: 10pt; vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"> Weighted-average discount rate-finance leases</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">9.3</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">%</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="text-align: right; font-size: 10pt">9.1</td> <td style="font-size: 10pt">%</td></tr> <tr style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left"> Weighted-average discount rate-operating leases</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">14.3</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">%</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="text-align: right; font-size: 10pt">14.4</td> <td style="font-size: 10pt">%</td></tr> </table>    The future maturities of the Company’s finance and operating leases as of September 30, 2020 is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Finance Leases</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Operating Leases</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 53%; color: #000000; text-align: left">2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; color: #000000; text-align: right">63</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; color: #000000; text-align: right">172</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; color: #000000; text-align: right">235</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">2021</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">196</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">701</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">897</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">2022</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">109</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">720</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">829</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">2023</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">5</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">705</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">710</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">2024</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">595</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">595</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2025 and thereafter</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total payments</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">373</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">2,894</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">3,267</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less amounts representing interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">(39</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">(717</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">(756</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total minimum payments required:</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">334</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">2,177</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">2,511</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: #000000; text-align: left"> </td></tr> </table>

Quantitative information regarding the Company’s leases is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended September 30,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Nine Months Ended September 30,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2019</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2019</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Components of lease cost</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Finance lease cost components:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 41%; text-align: left"> Amortization of finance lease assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; color: #000000; text-align: right">17</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; color: #000000; text-align: right">18</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; color: #000000; text-align: right">54</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; color: #000000; text-align: right">52</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">      Interest on finance lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">9</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">14</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">30</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">44</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">     Total finance lease costs</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">26</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">32</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">84</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">96</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating lease cost components:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">    Operating lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">140</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">129</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">425</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">375</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">    Variable lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">27</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">27</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">81</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">81</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">    Short-term lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">10</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">16</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">68</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">      Total operating lease costs</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">177</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">172</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">518</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">524</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> Total lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">203</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">204</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">602</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">620</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: #000000; text-align: left"> </td></tr> </table>

The future maturities of the Company’s finance and operating leases as of September 30, 2020 is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Finance Leases</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Operating Leases</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 53%; color: #000000; text-align: left">2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; color: #000000; text-align: right">63</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; color: #000000; text-align: right">172</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; color: #000000; text-align: right">235</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">2021</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">196</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">701</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">897</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">2022</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">109</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">720</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">829</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">2023</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">5</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">705</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">710</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">2024</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">595</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">595</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2025 and thereafter</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">—</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total payments</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">373</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">2,894</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">3,267</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less amounts representing interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">(39</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">(717</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">(756</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #000000; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total minimum payments required:</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">334</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">2,177</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">2,511</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; color: #000000; text-align: left"> </td></tr> </table>

(10) Share-Based Compensation   We follow FASB ASC Topic 718, Compensation – Stock Compensation, in which compensation expense is recognized only for share-based payments expected to vest. We recognized compensation expense related to stock options of $48 and $147 for the three and nine months ended September 30, 2020, respectively, compared to $64 and $179 for the three and nine months ended September 30, 2019, respectively.   As of September 30, 2020, there was approximately $290 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under our stock option plans. That cost is expected to be recognized over a remaining weighted-average period of 1.8 years.   Stock Options and Stock Grants   During the nine months ended September 30, 2020, 78,277 stock options were exercised for $23. During the nine months ended September 30, 2019, 36,000 stock options were exercised for $16.  During the nine months ended September 30, 2020, 535,000 stock options were granted, compared to 547,500 stock options granted during the same period in 2019. During the nine months ended September 30, 2020, 460,640 stock options expired compared to 130,500 for the same period in 2019. For the nine months ended September 30, 2020, 202,134 stock options were forfeited compared to 48,600 for the same period in 2019. We had 3,507,073 stock options outstanding at a weighted average exercise price of $0.58 on September 30, 2020, compared to 3,747,400 stock options outstanding at a weighted average exercise price of $0.64 on September 30, 2019.   No stock options were granted in the three-month periods ending September 30, 2020 and 2019.   The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for stock options granted during the nine months periods presented:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">For the nine months ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2019</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left; text-indent: 10pt; padding-left: 5.4pt">Weighted-average risk-free interest rates</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">0.5</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">2.3</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt; padding-left: 5.4pt">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt; padding-left: 5.4pt">Weighted-average expected life of the option</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7 years</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7 years</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt; padding-left: 5.4pt">Weighted-average expected stock price volatility</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">94</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">94</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt; padding-left: 5.4pt">Weighted-average fair value of the options granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.36</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.41</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>   As of September 30, 2020, we did not have any unvested restricted stock or performance shares outstanding.

250000 125000 2 250000

165000

497000

334000

34000

47000

22000

18000

1541000

734000

67000

200000

10000000

The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for stock options granted during the nine months periods presented:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">For the nine months ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2019</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left; text-indent: 10pt; padding-left: 5.4pt">Weighted-average risk-free interest rates</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">0.5</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">2.3</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt; padding-left: 5.4pt">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt; padding-left: 5.4pt">Weighted-average expected life of the option</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7 years</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7 years</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt; padding-left: 5.4pt">Weighted-average expected stock price volatility</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">94</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">94</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt; padding-left: 5.4pt">Weighted-average fair value of the options granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.36</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.41</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

205000

Supplemental cash flow information related to leases is as follows for the nine months ended:   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%"> <tr style="font-size: 10pt; vertical-align: bottom"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt">September 30, 2020</td> <td style="font-size: 10pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">September 30, 2019</td></tr> <tr style="font-size: 10pt; vertical-align: bottom"> <td style="font-size: 10pt; text-align: left">Cash paid for amounts included in the measurement of liabilities:</td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="text-align: right; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td></tr> <tr style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">           Operating cash outflow from operating leases</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; color: #000000; text-align: right">518</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #000000; text-align: left"> </td> <td style="font-size: 10pt; width: 2%"> </td> <td style="font-size: 10pt; width: 1%">$</td> <td style="text-align: right; font-size: 10pt; width: 9%">509</td> <td style="font-size: 10pt; width: 1%"> </td></tr> <tr style="font-size: 10pt; vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Right-of-use assets obtained in exchange for lease obligations: </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="text-align: right; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td></tr> <tr style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">           Operating leases </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">—</td><td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt">$</td> <td style="text-align: right; font-size: 10pt">205</td> <td style="font-size: 10pt"> </td></tr> <tr style="font-size: 10pt; vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"> Weighted-average remaining lease term-finance leases (in years)</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">1.9</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="text-align: right; font-size: 10pt">2.2</td> <td style="font-size: 10pt"> </td></tr> <tr style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left"> Weighted-average remaining lease term-operating leases (in years)</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">3.4</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="text-align: right; font-size: 10pt">3.3</td> <td style="font-size: 10pt"> </td></tr> <tr style="font-size: 10pt; vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"> Weighted-average discount rate-finance leases</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">9.3</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">%</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="text-align: right; font-size: 10pt">9.1</td> <td style="font-size: 10pt">%</td></tr> <tr style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left"> Weighted-average discount rate-operating leases</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000"> </td> <td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: right">14.3</td><td style="font: 10pt Times New Roman, Times, Serif; color: #000000; text-align: left">%</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="text-align: right; font-size: 10pt">14.4</td> <td style="font-size: 10pt">%</td></tr> </table>

EX-101.SCH 6 nanx-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited Consolidated Condensed) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Going Concern / Liquidity link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Revenues link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Notes and Line of Credit link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Significant Customers and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Business Segmentation and Geographical Distribution link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Business Segmentation and Geographical Distribution (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Going Concern / Liquidity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Revenues (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Earnings Per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Notes and Line of Credit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Lease (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Lease (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Lease (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Lease (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Significant Customers and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Business Segmentation and Geographical Distribution (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Business Segmentation and Geographical Distribution (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 nanx-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 nanx-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 nanx-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Plan Name [Axis] Paycheck Protection Program [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Short-term Debt, Type [Axis] Term Loan [Member] Credit Facility [Axis] Revolving Credit Facility [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Joint Development Agreement [Member] Legal Entity [Axis] Sumitomo Corporation of Americas [Member] Revolver Facility [Member] Business Loan Agreement [Member] Counterparty Name [Axis] Beachcorp, LLC [Member] Letter of Credit [Member] First Amendment Too Our Master Agreement [Member] Term Loan and The Revolver Facility [Member] Loan Restructuring Modification [Axis] Extended Maturity [Member] Asset-Based Revolving Loan Facility [Member] Credit Facility [Member] Long-term Debt, Type [Axis] 2% Secured Convertible Promissory Note Due on May 15, 2024 [Member] Related Party [Axis] Bradford T. Whitmore [Member] Line of Credit [Member] Business Loan Agreement [Member] Libertyville [Member] Award Type [Axis] Stock Options [Member] Supply Commitment [Axis] BASF [Member] Range [Axis] Greater than [Member] Less than [Member] Customer [Axis] Customer One [Member] Customer Two [Member] Customer Three [Member] Customer Four [Member] Product and Service [Axis] Personal Care Ingredients [Member] Advanced Materials [Member] Solesence [Member] Geographical [Axis] International Sources [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Product Revenue [Member] Other Revenue [Member] Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Document Period End Date Entity File Number Entity Incorporation, State Code Current Fiscal Year End Date Entity Reporting Status Current Entity Interactive Data Current Entity Small Business Entity Filer Category Entity Emerging Growth Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets: Cash Trade accounts receivable, less allowance for doubtful accounts of $9 on September 30, 2020 and on December 31, 2019, respectively Inventories, net Prepaid expenses and other current assets Total current assets Equipment and leasehold improvements, net Operating leases, right-of-use Other assets, net TOTAL ASSETS LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Line of credit, bank Line of credit, related party Current portion of long-term debt, related party Current portion of finance lease obligations Current portion of operating lease obligations Accounts payable Current portion of deferred revenue Accrued expenses Total current liabilities Long-term portion of finance lease obligations Long-term portion of operating lease obligations Long-term convertible loan, related party PPP Loan SBA Long-term portion of deferred revenue Asset retirement obligations Total long-term liabilities Contingent liabilities Stockholders' equity: Preferred stock, $.01 par value, 24,088 shares authorized and no shares issued and outstanding Common stock, $.01 par value, 55,000,000 shares authorized; 38,215,069 and 38,136,792 shares issued and outstanding on September 30, 2020 and December 31, 2019, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Allowance for doubtful accounts Preferred stock, par value (in dollars per share) Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value (in dollars per share) Common stock, authorized Common stock, issued Common stock, outstanding Statement [Table] Statement [Line Items] Revenue: Total revenue Operating expense: Cost of good revenue Gross profit Research and development expense Selling, general and administrative expense Income/(loss) from operations Interest expense Income/(loss) before provision for income taxes Provision for income taxes Net income/(loss) Net income/(loss) per basic shares (in dollars per share) Weighted average number of basic common shares outstanding (in shares) Net income/(loss) per diluted share (in dollars per share) Weighted average number of diluted common shares outstanding (in shares) Preferred Stock [Member] Increase (Decrease) in Shareholders' Equity [Roll Forward] Balance at beginning Balance at beginning (in shares) Stock option exercises Stock option exercises (in shares) Stock-based compensation Issuance of common stock Issuance of common stock (in shares) Stock conversion rights Net loss Balance at ending Balance at ending (in shares) Statement of Cash Flows [Abstract] Operating Activities: Net income (loss) Adjustements to reconcile net loss to cash used in operating activities: Depreciation and amortization Loss on disposal of equipment and leasehold improvements Share-based compensation Amortization of debt discount Changes in assets and liabilities related to operations: Trade accounts receivable Inventories Prepaid expenses and other assets Accounts payable Accrued expenses Deferred revenue Other long-term assets and liabilities Net cash used in operating activities Investing activities: Acquisition of equipment and leasehold improvements Net cash used in investing activities Financing activities: Principal payments on finance leases Proceeds from line of credit, bank Payments to the line of credit, bank Proceeds from the line of credit, related party Payments to the line of credit, related party Proceeds from PPP / SBA Loan Proceeds from issuance of common stock Proceeds from stock option exercises Net cash provided by financing activities Increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental cash flow information: Interest paid Supplemental non-cash investing and finacing activities: Accounts payable incurred for the purchase of equipment and leasehold improvements Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Presentation Going Concern Liquidity [Abstract] Going Concern / Liquidity Description Of Business Description of Business EX-101.PRE 10 nanx-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2020	Nov. 16, 2020
Cover [Abstract]
Entity Registrant Name	NANOPHASE TECHNOLOGIES Corp
Entity Central Index Key	0000883107
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Entity File Number	000-22333
Entity Incorporation, State Code	DE
Current Fiscal Year End Date	--12-31
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		38,215,792
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash	$ 1,134	$ 1,194
Trade accounts receivable, less allowance for doubtful accounts of $9 on September 30, 2020 and on December 31, 2019, respectively	2,451	970
Inventories, net	3,584	2,554
Prepaid expenses and other current assets	599	267
Total current assets	7,768	4,985
Equipment and leasehold improvements, net	2,650	2,255
Operating leases, right-of-use	1,917	2,119
Other assets, net	11	13
TOTAL ASSETS	12,346	9,372
Current liabilities:
Line of credit, bank	500	500
Line of credit, related party	1,541	224
Current portion of long-term debt, related party	500	500
Current portion of finance lease obligations	186	218
Current portion of operating lease obligations	411	357
Accounts payable	1,668	1,748
Current portion of deferred revenue	309	482
Accrued expenses	647	380
Total current liabilities	5,762	4,409
Long-term portion of finance lease obligations	148	288
Long-term portion of operating lease obligations	1,766	2,035
Long-term convertible loan, related party	1,030	830
PPP Loan SBA	952
Long-term portion of deferred revenue		93
Asset retirement obligations	212	206
Total long-term liabilities	4,108	3,452
Contingent liabilities
Stockholders' equity:
Preferred stock, $.01 par value, 24,088 shares authorized and no shares issued and outstanding
Common stock, $.01 par value, 55,000,000 shares authorized; 38,215,069 and 38,136,792 shares issued and outstanding on September 30, 2020 and December 31, 2019, respectively	382	381
Additional paid-in capital	102,055	101,886
Accumulated deficit	(99,961)	(100,756)
Total stockholders' equity	2,476	1,511
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 12,346	$ 9,372

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 9	$ 9
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized	24,088	24,088
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized	55,000,000	55,000,000
Common stock, issued	38,215,069	38,136,792
Common stock, outstanding	38,215,069	38,136,792

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue:
Total revenue	$ 3,888	$ 3,069	$ 12,262	$ 10,118
Operating expense:
Cost of good revenue	2,201	2,506	7,832	7,839
Gross profit	1,687	563	4,430	2,279
Research and development expense	405	488	1,134	1,450
Selling, general and administrative expense	730	890	2,133	2,711
Income/(loss) from operations	552	(815)	1,163	(1,882)
Interest expense	122	47	368	140
Income/(loss) before provision for income taxes	430	(862)	795	(2,022)
Provision for income taxes
Net income/(loss)	$ 430	$ (862)	$ 795	$ (2,022)
Net income/(loss) per basic shares (in dollars per share)	$ 0.01	$ (0.02)	$ 0.02	$ (0.06)
Weighted average number of basic common shares outstanding (in shares)	38,141,741	38,136,792	38,138,453	36,077,257
Net income/(loss) per diluted share (in dollars per share)	$ 0.01	$ (0.02)	$ 0.02	$ (0.06)
Weighted average number of diluted common shares outstanding (in shares)	38,432,741	38,136,792	38,228,453	36,077,257
Product Revenue [Member]
Revenue:
Total revenue	$ 3,827	$ 3,043	$ 11,929	$ 9,797
Other Revenue [Member]
Revenue:
Total revenue	$ 61	$ 26	$ 333	$ 321

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited Consolidated Condensed) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at beginning at Dec. 31, 2018	$ 339	$ 98,795	$ (97,750)	$ 1,384
Balance at beginning (in shares) at Dec. 31, 2018	33,911,792
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Stock-based compensation		57		57
Net loss			(513)	(513)
Balance at ending at Mar. 31, 2019	$ 339	98,852	(98,263)	928
Balance at ending (in shares) at Mar. 31, 2019	33,911,792
Balance at beginning at Dec. 31, 2018	$ 339	98,795	(97,750)	1,384
Balance at beginning (in shares) at Dec. 31, 2018	33,911,792
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Net loss				(2,022)
Balance at ending at Sep. 30, 2019	$ 381	100,624	(99,772)	1,233
Balance at ending (in shares) at Sep. 30, 2019	38,136,792
Balance at beginning at Mar. 31, 2019	$ 339	98,852	(98,263)	928
Balance at beginning (in shares) at Mar. 31, 2019	33,911,792
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Stock option exercises		16		16
Stock option exercises (in shares)	36,000
Stock-based compensation		58		58
Issuance of common stock	$ 42	1,634		1,676
Issuance of common stock (in shares)	4,189,000
Net loss			(647)	(647)
Balance at ending at Jun. 30, 2019	$ 381	100,560	(98,910)	2,031
Balance at ending (in shares) at Jun. 30, 2019	38,136,792
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Stock-based compensation		64		64
Net loss			(862)	(862)
Balance at ending at Sep. 30, 2019	$ 381	100,624	(99,772)	1,233
Balance at ending (in shares) at Sep. 30, 2019	38,136,792
Balance at beginning at Dec. 31, 2019	$ 381	101,886	(100,756)	1,511
Balance at beginning (in shares) at Dec. 31, 2019	38,136,792
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Stock-based compensation		52		52
Net loss			(167)	(167)
Balance at ending at Mar. 31, 2020	$ 381	101,938	(100,923)	1,396
Balance at ending (in shares) at Mar. 31, 2020	38,136,792
Balance at beginning at Dec. 31, 2019	$ 381	101,886	(100,756)	1,511
Balance at beginning (in shares) at Dec. 31, 2019	38,136,792
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Net loss				795
Balance at ending at Sep. 30, 2020	$ 382	102,055	(99,961)	2,476
Balance at ending (in shares) at Sep. 30, 2020	38,215,069
Balance at beginning at Mar. 31, 2020	$ 381	101,938	(100,923)	1,396
Balance at beginning (in shares) at Mar. 31, 2020	38,136,792
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Stock-based compensation		47		47
Net loss			532	532
Balance at ending at Jun. 30, 2020	$ 381	101,985	(100,391)	1,975
Balance at ending (in shares) at Jun. 30, 2020	38,136,792
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Stock option exercises	$ 1	22		23
Stock option exercises (in shares)	78,277
Stock-based compensation		48		48
Net loss			430	430
Balance at ending at Sep. 30, 2020	$ 382	$ 102,055	$ (99,961)	$ 2,476
Balance at ending (in shares) at Sep. 30, 2020	38,215,069

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating Activities:
Net income (loss)	$ 795	$ (2,022)
Adjustements to reconcile net loss to cash used in operating activities:
Depreciation and amortization	265	234
Loss on disposal of equipment and leasehold improvements		16
Share-based compensation	147	179
Amortization of debt discount	200
Changes in assets and liabilities related to operations:
Trade accounts receivable	(1,481)	(544)
Inventories	(1,030)	98
Prepaid expenses and other assets	(332)	(12)
Accounts payable	(284)	(632)
Accrued expenses	267	(19)
Deferred revenue	(266)	594
Other long-term assets and liabilities	(13)	(53)
Net cash used in operating activities	(1,732)	(2,161)
Investing activities:
Acquisition of equipment and leasehold improvements	(448)	(523)
Net cash used in investing activities	(448)	(523)
Financing activities:
Principal payments on finance leases	(172)	(162)
Proceeds from line of credit, bank	1,500	1,000
Payments to the line of credit, bank	(1,500)	(500)
Proceeds from the line of credit, related party	10,390	8,166
Payments to the line of credit, related party	(9,073)	(7,895)
Proceeds from PPP / SBA Loan	952
Proceeds from issuance of common stock		1,676
Proceeds from stock option exercises	23	16
Net cash provided by financing activities	2,120	2,301
Increase (decrease) in cash and cash equivalents	(60)	(383)
Cash and cash equivalents at beginning of period	1,194	1,345
Cash and cash equivalents at end of period	1,134	962
Supplemental cash flow information:
Interest paid	152	126
Supplemental non-cash investing and finacing activities:
Accounts payable incurred for the purchase of equipment and leasehold improvements	$ 204	$ 18

XML 17 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation

9 Months Ended

Sep. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

(1) Basis of Presentation

XML 18 R8.htm IDEA: XBRL DOCUMENT

Going Concern / Liquidity

9 Months Ended

Sep. 30, 2020

Going Concern Liquidity [Abstract]

Going Concern / Liquidity

(2) Going Concern / Liquidity

XML 19 R9.htm IDEA: XBRL DOCUMENT

Description of Business

9 Months Ended

Sep. 30, 2020

Description Of Business

Description of Business

(3) Description of Business

XML 20 R10.htm IDEA: XBRL DOCUMENT

Revenues

9 Months Ended

Sep. 30, 2020

Revenue from Contract with Customer [Abstract]

Revenues

(4) Revenues

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

Earnings Per Share

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Earnings Per Share

(5) Earnings Per Share

XML 22 R12.htm IDEA: XBRL DOCUMENT

Financial Instruments

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Financial Instruments

(6) Financial Instruments

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 23 R13.htm IDEA: XBRL DOCUMENT

Notes and Line of Credit

9 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

Notes and Lines of Credit

(7) Notes and Line of Credit

XML 24 R14.htm IDEA: XBRL DOCUMENT

Inventories

9 Months Ended

Sep. 30, 2020

Inventory Disclosure [Abstract]

Inventories

(8) Inventories

Inventories consist of the following:

	September 30, 2020			December 31, 2019

Raw materials	$	2,187		$	1,425
Finished goods		1,427			1,170
		3,614			2,595
Allowance for excess inventory quantities		(30	)		(41	)
	$	3,584		$	2,554

XML 25 R15.htm IDEA: XBRL DOCUMENT

Leases

9 Months Ended

Sep. 30, 2020

Leases [Abstract]

Leases

(9) Leases

Quantitative information regarding the Company’s leases is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Components of lease cost
Finance lease cost components:
Amortization of finance lease assets	$	17	$	18	$	54	$	52
Interest on finance lease liabilities		9		14		30		44
Total finance lease costs	$	26	$	32	$	84	$	96
Operating lease cost components:
Operating lease cost	$	140	$	129	$	425	$	375
Variable lease cost		27		27		81		81
Short-term lease cost		10		16		12		68
Total operating lease costs	$	177	$	172	$	518	$	524
Total lease cost	$	203	$	204	$	602	$	620

Supplemental cash flow information related to leases is as follows for the nine months ended:

	September 30, 2020			September 30, 2019
Cash paid for amounts included in the measurement of liabilities:
Operating cash outflow from operating leases	$	518		$	509
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	—		$	205
Weighted-average remaining lease term-finance leases (in years)		1.9			2.2
Weighted-average remaining lease term-operating leases (in years)		3.4			3.3
Weighted-average discount rate-finance leases		9.3	%		9.1	%
Weighted-average discount rate-operating leases		14.3	%		14.4	%

The future maturities of the Company’s finance and operating leases as of September 30, 2020 is as follows:

	Finance Leases			Operating Leases			Total
2020	$	63		$	172		$	235
2021		196			701			897
2022		109			720			829
2023		5			705			710
2024		—			595			595
2025 and thereafter		—			1			1
Total payments	$	373		$	2,894		$	3,267
Less amounts representing interest		(39	)		(717	)		(756	)
Total minimum payments required:	$	334		$	2,177		$	2,511

XML 26 R16.htm IDEA: XBRL DOCUMENT

Share-Based Compensation

9 Months Ended

Sep. 30, 2020

Share-based Payment Arrangement [Abstract]

Share-Based Compensation

(10) Share-Based Compensation

Stock Options and Stock Grants

No stock options were granted in the three-month periods ending September 30, 2020 and 2019.

The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for stock options granted during the nine months periods presented:

For the nine months ended	September 30, 2020			September 30, 2019
Weighted-average risk-free interest rates		0.5	%		2.3	%
Dividend yield		0.00	%		0.00	%
Weighted-average expected life of the option		7 years			7 years
Weighted-average expected stock price volatility		94	%		94	%
Weighted-average fair value of the options granted	$	0.36		$	0.41

As of September 30, 2020, we did not have any unvested restricted stock or performance shares outstanding.

XML 27 R17.htm IDEA: XBRL DOCUMENT

Significant Customers and Contingencies

9 Months Ended

Sep. 30, 2020

Risks and Uncertainties [Abstract]

Significant Customers and Contingencies

(11) Significant Customers and Contingencies

XML 28 R18.htm IDEA: XBRL DOCUMENT

Business Segmentation and Geographical Distribution

9 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

Business Segmentation and Geographical Distribution

(12) Business Segmentation and Geographical Distribution

	For the three months ended September 30,				For the nine months ended September 30,
Product Category	2020		2019		2020		2019
Personal Care Ingredients	$	753	$	2,304	$	4,190	$	6,464
Advanced Materials		1,582		388		3,678		1,988
Solésence®		1,553		377		4,394		1,666
Total Sales	$	3,888	$	3,069	$	12,262	$	10,118

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

XML 29 R19.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

9 Months Ended

Sep. 30, 2020

Inventory Disclosure [Abstract]

Schedule of inventories

Inventories consist of the following:

	September 30, 2020			December 31, 2019

Raw materials	$	2,187		$	1,425
Finished goods		1,427			1,170
		3,614			2,595
Allowance for excess inventory quantities		(30	)		(41	)
	$	3,584		$	2,554

XML 30 R20.htm IDEA: XBRL DOCUMENT

Leases (Tables)

9 Months Ended

Sep. 30, 2020

Leases [Abstract]

Summary of quantitative information about leases

Quantitative information regarding the Company’s leases is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Components of lease cost
Finance lease cost components:
Amortization of finance lease assets	$	17	$	18	$	54	$	52
Interest on finance lease liabilities		9		14		30		44
Total finance lease costs	$	26	$	32	$	84	$	96
Operating lease cost components:
Operating lease cost	$	140	$	129	$	425	$	375
Variable lease cost		27		27		81		81
Short-term lease cost		10		16		12		68
Total operating lease costs	$	177	$	172	$	518	$	524
Total lease cost	$	203	$	204	$	602	$	620

Summary of supplemental cash flow information related to leases

Supplemental cash flow information related to leases is as follows for the nine months ended:

	September 30, 2020			September 30, 2019
Cash paid for amounts included in the measurement of liabilities:
Operating cash outflow from operating leases	$	518		$	509
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	—		$	205
Weighted-average remaining lease term-finance leases (in years)		1.9			2.2
Weighted-average remaining lease term-operating leases (in years)		3.4			3.3
Weighted-average discount rate-finance leases		9.3	%		9.1	%
Weighted-average discount rate-operating leases		14.3	%		14.4	%

Schedule of future maturities of finance and operating leases

The future maturities of the Company’s finance and operating leases as of September 30, 2020 is as follows:

	Finance Leases			Operating Leases			Total
2020	$	63		$	172		$	235
2021		196			701			897
2022		109			720			829
2023		5			705			710
2024		—			595			595
2025 and thereafter		—			1			1
Total payments	$	373		$	2,894		$	3,267
Less amounts representing interest		(39	)		(717	)		(756	)
Total minimum payments required:	$	334		$	2,177		$	2,511

XML 31 R21.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2020

Share-based Payment Arrangement [Abstract]

Schedule of assumptions used to calculate black-scholes option pricing model for options granted

The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for stock options granted during the nine months periods presented:

For the nine months ended	September 30, 2020			September 30, 2019
Weighted-average risk-free interest rates		0.5	%		2.3	%
Dividend yield		0.00	%		0.00	%
Weighted-average expected life of the option		7 years			7 years
Weighted-average expected stock price volatility		94	%		94	%
Weighted-average fair value of the options granted	$	0.36		$	0.41

XML 32 R22.htm IDEA: XBRL DOCUMENT

Business Segmentation and Geographical Distribution (Tables)

9 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

Schedule of revenue by category

The revenues for the three months and nine months ended September 30, 2020 and 2019, by category, are as follows:

	For the three months ended September 30,				For the nine months ended September 30,
Product Category	2020		2019		2020		2019
Personal Care Ingredients	$	753	$	2,304	$	4,190	$	6,464
Advanced Materials		1,582		388		3,678		1,988
Solésence®		1,553		377		4,394		1,666
Total Sales	$	3,888	$	3,069	$	12,262	$	10,118

XML 33 R23.htm IDEA: XBRL DOCUMENT

Going Concern / Liquidity (Details Narrative) - USD ($) $ in Thousands		12 Months Ended
	Apr. 17, 2020	Dec. 31, 2019	Sep. 30, 2020
Revolving Credit Facility [Member]
Maximum credit limit	$ 2,750
Term Loan [Member]
Loan face value	$ 500
Maturity date	Mar. 31, 2021
Customer Concentration Risk [Member] \| Revenue Benchmark [Member]
Concentration risk (percent)		63.00%
Paycheck Protection Program [Member]
Loan face value	$ 952		$ 952
Accrues interest	1.00%
Payment terms	PPP note in eighteen equal monthly installments, with the first payment being due on a date yet to be determined. The Company is in the process of applying for loan forgiveness and does not expect resolution until the first quarter of 2021.

XML 34 R24.htm IDEA: XBRL DOCUMENT

Revenues (Details Narrative) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended		14 Months Ended
Revenues (Details Narrative) $ in Thousands	Jul. 31, 2019 USD ($) Number	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)
Customer deposits		$ 309		$ 309		$ 309	$ 575
Revenue		3,888	$ 3,069	12,262	$ 10,118
Joint Development Agreement [Member] \| Sumitomo Corporation of Americas [Member]
Initial term agreement	10 years
Commitment fee per agreement	$ 250
Contingent fees per agreement	$ 125
Number of contingent fee payments \| Number	2
Refundable commitment fee per agreement	$ 250
Revenue		$ 47		$ 229		$ 250

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 35 R25.htm IDEA: XBRL DOCUMENT

Earnings Per Share (Details Narrative) - shares	3 Months Ended	9 Months Ended
Earnings Per Share (Details Narrative) - shares	Sep. 30, 2019	Sep. 30, 2019
Earnings Per Share [Abstract]
Common stock outstanding not included in computation of diluted earnings (loss) per share	165,000	497,000

XML 36 R26.htm IDEA: XBRL DOCUMENT

Notes and Line of Credit (Details Narrative) $ / shares in Units, $ in Thousands									1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 29, 2020 USD ($)	Jun. 29, 2020 USD ($)	Apr. 17, 2020 USD ($)	Mar. 30, 2020 USD ($)	Mar. 23, 2020	Nov. 20, 2019 USD ($) $ / shares	Mar. 22, 2019 USD ($) Number	Nov. 16, 2018 USD ($)	Jul. 31, 2014 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Dec. 31, 2019 USD ($)	Sep. 08, 2020 USD ($)
Interest expense paid										$ 122	$ 47	$ 368	$ 140
Paycheck Protection Program [Member]
Term loan			$ 952							952		952
Interest rate			1.00%
Payment terms			PPP note in eighteen equal monthly installments, with the first payment being due on a date yet to be determined. The Company is in the process of applying for loan forgiveness and does not expect resolution until the first quarter of 2021.
2% Secured Convertible Promissory Note Due on May 15, 2024 [Member] \| Bradford T. Whitmore [Member]
Interest rate						2.00%
Maturity date						May 15, 2024
Principal amount						$ 2,000
Debt conversion price (in dollars per share) \| $ / shares						$ 0.20
Share price (in dollars per share) \| $ / shares						$ 0.32
Discount on the convertible note						$ 1,200				1,103		1,103		$ 1,170
Balance as of convertible note										1,030		1,030		830
Accreted amount										67		200
Asset-Based Revolving Loan Facility [Member]
Maximum borrowing capacity			$ 2,750
Amount outstanding										1,541		1,541
Excess borrowing capacity										734		734
Business Loan Agreement [Member] \| Beachcorp, LLC [Member]
Maximum borrowing capacity								$ 500							$ 2,750
Term loan								$ 2,000		500		500
Interest rate								8.25%
Maturity date								Dec. 31, 2020
Ownership percentage								63.00%
Total interest expense										34	47	334
Interest expense paid										22	18
Accrued interest expense on related party										12	$ 9
Business Loan Agreement [Member] \| Beachcorp, LLC [Member] \| Bradford T. Whitmore [Member]
Maximum borrowing capacity										734		734
Business Loan Agreement [Member] \| Beachcorp, LLC [Member] \| Asset-Based Revolving Loan Facility [Member]
Basis spread variable interest rate								3.00%
Variable interest rate basis								Prime rate
Maximum borrowing capacity								$ 2,000
Facility, expiration date								Mar. 31, 2020
First Amendment Too Our Master Agreement [Member] \| Beachcorp, LLC [Member] \| Term Loan and The Revolver Facility [Member] \| Extended Maturity [Member]
Maturity date					Mar. 31, 2021
Term loan collateral					Secured by all the unencumbered assets of the Company
Letter of Credit [Member]
Letter of credit and related promissory note									$ 30
Basis spread variable interest rate									1.00%
Variable interest rate basis									Prime rate
Facility, expiration date									Jul. 01, 2021
Line of Credit [Member] \| Business Loan Agreement [Member] \| Libertyville [Member]
Basis spread variable interest rate							1.00%
Variable interest rate basis							Prime rate
Maximum borrowing capacity	$ 500	$ 500		$ 500			$ 500			$ 500		500		$ 500
Repayments of lines of credit date	Oct. 02, 2020	Jul. 01, 2020		Apr. 02, 2020										Jan. 02, 2020
Borrowing capacity as percentage of accounts receivable							75.00%
Borrowing capacity as multiple of accounts receivable \| Number							2
Minimum amount of cash on hand before advance is given							$ 500
Facility, expiration date							Apr. 20, 2021
Credit Facility [Member]
Accrued interest expense on related party												$ 27		$ 10

XML 37 R27.htm IDEA: XBRL DOCUMENT

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 2,187	$ 1,425
Finished goods	1,427	1,170
Total inventory, gross	3,614	2,595
Allowance for excess inventory quantities	(30)	(41)
Total inventory	$ 3,584	$ 2,554

XML 38 R28.htm IDEA: XBRL DOCUMENT

Lease (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Lease (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Finance lease cost components:
Amortization of finance lease assets	$ 17	$ 18	$ 54	$ 52
Interest on finance lease liabilities	9	14	30	44
Total finance lease costs	26	32	84	96
Operating lease cost components:
Operating lease cost	140	129	425	375
Variable lease cost	27	27	81	81
Short-term lease cost	10	16	12	68
Total operating lease costs	177	172	518	524
Total lease cost	$ 203	$ 204	$ 602	$ 620

XML 39 R29.htm IDEA: XBRL DOCUMENT

Lease (Details 1) - USD ($) $ in Thousands	9 Months Ended
Lease (Details 1) - USD ($) $ in Thousands	Sep. 30, 2020	Sep. 30, 2019
Cash paid for amounts included in the measurement of liabilities:
Operating cash outflow from operating leases	$ 518	$ 509
Right-of-use assets obtained in exchange for lease obligations: Operating leases		$ 205
Weighted-average remaining lease term-finance leases (in years)	1 year 10 months 25 days	2 years 2 months 12 days
Weighted-average remaining lease term-operating leases (in years)	3 years 4 months 24 days	3 years 3 months 19 days
Weighted-average discount rate-finance leases	9.30%	9.10%
Weighted-average discount rate-operating leases	14.30%	14.40%

XML 40 R30.htm IDEA: XBRL DOCUMENT

Lease (Details 2) $ in Thousands	Sep. 30, 2020 USD ($)
Operating Leases:
2020	$ 172
2021	701
2022	720
2023	705
2024	595
2025 and thereafter	1
Total payments	2,894
Less amounts representing interest	(717)
Total minimum payments required:	2,177
Finance Leases:
2020	63
2021	196
2022	109
2023	5
Total payments	373
Less amounts representing interest	(39)
Total minimum payments required:	334
Total:
2020	235
2021	897
2022	829
2023	710
2024	595
2025 and thereafter	1
Total payments	3,267
Less amounts representing interest	(756)
Total minimum payments required:	$ 2,511

XML 41 R31.htm IDEA: XBRL DOCUMENT

Lease (Details Narrative) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Leases [Abstract]
Operating lease right-of-use assets	$ 1,917	$ 2,119
Current portion of operating lease obligations	411	357
Long-term portion of operating lease obligations	$ 1,766	$ 2,035

XML 42 R32.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details) - Stock Options [Member] - $ / shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Weighted-average risk-free interest rates	0.50%	2.30%
Dividend yield	0.00%	0.00%
Weighted-average expected life of the option	7 years	7 years
Weighted-average expected stock price volatility	94.00%	94.00%
Weighted-average fair value of the options granted	$ 0.36	$ 0.41

XML 43 R33.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Total unrecognized compensation cost related to nonvested share-based compensation arrangements granted	$ 290			$ 290
Weighted-average period over which unrecognized compensation is expected to be recognized				1 year 9 months 18 days
Vlaue of stock options exercised	23		$ 16
Stock Options [Member]
Share-based compensation expense	$ 48	$ 64		$ 147	$ 179
Stock options granted				535,000	547,500
Number of stock options excercised				78,277	36,000
Vlaue of stock options exercised				$ 23	$ 16
Stock options expired				460,640	130,500
Stock options forfeited				202,134	48,600
Stock options outstanding, end of period	3,507,073	3,747,400		3,507,073	3,747,400
Weighted average exercise price	$ 0.58	$ 0.64		$ 0.58	$ 0.64

XML 44 R34.htm IDEA: XBRL DOCUMENT

Significant Customers and Contingencies (Details Narrative) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) Number	Sep. 30, 2019 USD ($) Number	Dec. 31, 2019 USD ($)
Number of major customers \| Number			4	4
Accounts receivable	$ 2,451		$ 2,451		$ 970
Deferred revenue	309		309		$ 482
Customer One [Member]
Accounts receivable	901	$ 0	901	$ 0
Customer Two [Member]
Accounts receivable	328	1,042	328	1,042
Customer Three [Member]
Accounts receivable	291	0	291	0
Customer Four [Member]
Accounts receivable	$ 420	$ 122	$ 420	$ 122
Customer Concentration Risk [Member] \| Revenue Benchmark [Member]
Revenue from customers					63.00%
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Customer One [Member]
Revenue from customers	30.00%	0.00%	20.00%	4.00%
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Customer Two [Member]
Revenue from customers	18.00%	75.00%	32.00%	64.00%
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Customer Three [Member]
Revenue from customers	16.00%	0.00%	13.00%	0.00%
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Customer Four [Member]
Revenue from customers	16.00%	4.00%	14.00%	9.00%
BASF [Member]
Cash requirements levels for safety stock	$ 1,000		$ 1,000
Equipment sale - net book value equipment	115.00%		115.00%
BASF [Member] \| Greater than [Member]
Total assets requirement under supply agreeement	$ 1,000		$ 1,000
Cash, cash equivalents and certain investments required under supply agreeement	500		500
Debt principal acceleration trigger amount	10,000		10,000
Finished goods inventory levels as safety stock	$ 500		$ 500
Equipment sale - original book value of equipment and upgrades	30.00%		30.00%
BASF [Member] \| Less than [Member]
Earnings trigger under supply agreeement			$ 0

XML 45 R35.htm IDEA: XBRL DOCUMENT

Business Segmentation and Geographical Distribution (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Sales	$ 3,888	$ 3,069	$ 12,262	$ 10,118
Personal Care Ingredients [Member]
Sales	753	2,304	4,190	6,464
Advanced Materials [Member]
Sales	1,582	388	3,678	1,988
Solesence [Member]
Sales	$ 1,553	$ 377	$ 4,394	$ 1,666

- Definition

+ References

+ Details

XML 46 R36.htm IDEA: XBRL DOCUMENT

Business Segmentation and Geographical Distribution (Details Narrative) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) Number	Sep. 30, 2019 USD ($)
Number of business segments \| Number			1
International Sources [Member]
Revenue from international sources \| $	$ 1,242	$ 33	$ 2,747	$ 734

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

8<[Q?D:GFQ(92.E!4DHY)Q,^DF2EVX:DZE^TKQ(LSS88+P=8R=Q@%\8#4 MCD#$3Z!M/NIJE9U6S M%3\;U9(K+A_YZ!PYI\=_;^AXHZCC& V\I?]"B]47\R[*I?H!<7A/U=^\6U = M@J@?07?R>5TH\XPQ>O,NP":9H$=6-'R,2#@.D@2I#9-FFZ'1&R'SO\'>O"-7 MXOE&KE2SNR@:K30\@O[%

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�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end XML 48 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 157 305 1 false 36 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://nanophase.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) Sheet http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) (Parenthetical) Sheet http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed) Sheet http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed) Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Unaudited Consolidated Condensed) Sheet http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquityUnauditedConsolidatedCondensed CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Unaudited Consolidated Condensed) Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed) Sheet http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed) Statements 6 false false R7.htm 00000007 - Disclosure - Basis of Presentation Sheet http://nanophase.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Going Concern / Liquidity Sheet http://nanophase.com/role/GoingConcernLiquidity Going Concern / Liquidity Notes 8 false false R9.htm 00000009 - Disclosure - Description of Business Sheet http://nanophase.com/role/DescriptionOfBusiness Description of Business Notes 9 false false R10.htm 00000010 - Disclosure - Revenues Sheet http://nanophase.com/role/Revenues Revenues Notes 10 false false R11.htm 00000011 - Disclosure - Earnings Per Share Sheet http://nanophase.com/role/EarningsPerShare Earnings Per Share Notes 11 false false R12.htm 00000012 - Disclosure - Financial Instruments Sheet http://nanophase.com/role/FinancialInstruments Financial Instruments Notes 12 false false R13.htm 00000013 - Disclosure - Notes and Line of Credit Notes http://nanophase.com/role/NotesAndLineOfCredit Notes and Line of Credit Notes 13 false false R14.htm 00000014 - Disclosure - Inventories Sheet http://nanophase.com/role/Inventories Inventories Notes 14 false false R15.htm 00000015 - Disclosure - Leases Sheet http://nanophase.com/role/Leases Leases Notes 15 false false R16.htm 00000016 - Disclosure - Share-Based Compensation Sheet http://nanophase.com/role/Share-basedCompensation Share-Based Compensation Notes 16 false false R17.htm 00000017 - Disclosure - Significant Customers and Contingencies Sheet http://nanophase.com/role/SignificantCustomersAndContingencies Significant Customers and Contingencies Notes 17 false false R18.htm 00000018 - Disclosure - Business Segmentation and Geographical Distribution Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution Business Segmentation and Geographical Distribution Notes 18 false false R19.htm 00000019 - Disclosure - Inventories (Tables) Sheet http://nanophase.com/role/InventoriesTables Inventories (Tables) Tables http://nanophase.com/role/Inventories 19 false false R20.htm 00000020 - Disclosure - Leases (Tables) Sheet http://nanophase.com/role/LeasesTables Leases (Tables) Tables http://nanophase.com/role/Leases 20 false false R21.htm 00000021 - Disclosure - Share-Based Compensation (Tables) Sheet http://nanophase.com/role/Share-basedCompensationTables Share-Based Compensation (Tables) Tables http://nanophase.com/role/Share-basedCompensation 21 false false R22.htm 00000022 - Disclosure - Business Segmentation and Geographical Distribution (Tables) Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables Business Segmentation and Geographical Distribution (Tables) Tables http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution 22 false false R23.htm 00000023 - Disclosure - Going Concern / Liquidity (Details Narrative) Sheet http://nanophase.com/role/GoingConcernLiquidityDetailsNarrative Going Concern / Liquidity (Details Narrative) Details http://nanophase.com/role/GoingConcernLiquidity 23 false false R24.htm 00000024 - Disclosure - Revenues (Details Narrative) Sheet http://nanophase.com/role/RevenuesDetailsNarrative Revenues (Details Narrative) Details http://nanophase.com/role/Revenues 24 false false R25.htm 00000025 - Disclosure - Earnings Per Share (Details Narrative) Sheet http://nanophase.com/role/EarningsPerShareDetailsNarrative Earnings Per Share (Details Narrative) Details http://nanophase.com/role/EarningsPerShare 25 false false R26.htm 00000026 - Disclosure - Notes and Line of Credit (Details Narrative) Notes http://nanophase.com/role/NotesAndLineOfCreditDetailsNarrative Notes and Line of Credit (Details Narrative) Details http://nanophase.com/role/NotesAndLineOfCredit 26 false false R27.htm 00000027 - Disclosure - Inventories (Details) Sheet http://nanophase.com/role/InventoriesDetails Inventories (Details) Details http://nanophase.com/role/InventoriesTables 27 false false R28.htm 00000028 - Disclosure - Lease (Details) Sheet http://nanophase.com/role/LeaseDetails Lease (Details) Details http://nanophase.com/role/LeasesTables 28 false false R29.htm 00000029 - Disclosure - Lease (Details 1) Sheet http://nanophase.com/role/LeaseDetails1 Lease (Details 1) Details http://nanophase.com/role/LeasesTables 29 false false R30.htm 00000030 - Disclosure - Lease (Details 2) Sheet http://nanophase.com/role/LeaseDetails2 Lease (Details 2) Details http://nanophase.com/role/LeasesTables 30 false false R31.htm 00000031 - Disclosure - Lease (Details Narrative) Sheet http://nanophase.com/role/LeaseDetailsNarrative Lease (Details Narrative) Details http://nanophase.com/role/LeasesTables 31 false false R32.htm 00000032 - Disclosure - Share-Based Compensation (Details) Sheet http://nanophase.com/role/Share-basedCompensationDetails Share-Based Compensation (Details) Details http://nanophase.com/role/Share-basedCompensationTables 32 false false R33.htm 00000033 - Disclosure - Share-Based Compensation (Details Narrative) Sheet http://nanophase.com/role/Share-basedCompensationDetailsNarrative Share-Based Compensation (Details Narrative) Details http://nanophase.com/role/Share-basedCompensationTables 33 false false R34.htm 00000034 - Disclosure - Significant Customers and Contingencies (Details Narrative) Sheet http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative Significant Customers and Contingencies (Details Narrative) Details http://nanophase.com/role/SignificantCustomersAndContingencies 34 false false R35.htm 00000035 - Disclosure - Business Segmentation and Geographical Distribution (Details) Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetails Business Segmentation and Geographical Distribution (Details) Details http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables 35 false false R36.htm 00000036 - Disclosure - Business Segmentation and Geographical Distribution (Details Narrative) Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative Business Segmentation and Geographical Distribution (Details Narrative) Details http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables 36 false false All Reports Book All Reports nanx-20200930.xml nanx-20200930.xsd nanx-20200930_cal.xml nanx-20200930_def.xml nanx-20200930_lab.xml nanx-20200930_pre.xml http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true ZIP 52 0001387131-20-010032-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001387131-20-010032-xbrl.zip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
\_F'9UMR\.'<$ME1Y-;TU9AT5N7HBVW$'#5,5@96VWDMN2%LHX2,YV@&LH^]O#HNS)HJ!< MUBIY?*VY'92%D;S:ZF[#X%Y!!T=C'7H-EW]'X#&HXH%R&H'&85'[E6V$D\"O MX2RV8,91J/6QCLVKI ? S!^R9D^9QM7CN_WGH\8TC[DL-)QU5=>;P*:"L"5T M>4TEAN2&LMH824[7 K)@.>P>-QD7<1!^7$ :BF"S$8%DV(/$Q@6 509S53_\ MV#[GS.G?RH33&,F!1/>DNJE1(M.5M[Z+_9AK3 %3Q1[X5^L:X#T/LU;)_QQL?#%H^.MY[C6V MC(/B[B$>=[DJ9#_F\M;&Q%/+L9:GZJ&Q\E!.L[SJ83G%&J&/CI"F4RMOY8,D MY4$<5OG4Q')(Y:^.C92F0RE?W4.DY$&<1;DJXG,&-;(,3-QTGCF-*N#06'K0 M1TVNRFW9)KCXN0TE<1TE>:(]A",D;55&'AV-+&-R+HXY*AI5 +8CHFW '^K1 MD+:N8]H% 3&]"7@0D_)$YT*V]+JC3GC\U<*FX/4_S?'5F?P,9R10+:6"$&?4 MTRI,S&?]-O)7@H'P!R?K>-7GV-L M11?-)K"W%A+*##=\/54.B#;VS=U7GSEL0QS--JVO$@[:#+=D_30.AS3V[==7 M'PALQ1EU#]57"0EG!KND?AH'Q!GK/NBKM^RWFZ":;=- MWN%P2<$<8&=]#,'4+7*'[+04&FR&6P5Q[(#[0-SOMK>-#I>K=5E ULIJ8]*( M79$+2P,#S#X%!D)8MI9= ,-O'WO9!S>-)[,%#@N >'+8PP;O'G?<^[<7!@EO M=3OO5H7 +PI[[,'[P74],L35M+TXSG=N'R)./PJ(,;R\1;-<)@H^X1R2" /# M/KYL1.HYZ>0IXO%%E'!X\QH:HERM97KAFR3_Y4*LOQOC!0G;#,T:X+MAG[H) MU(S]EW/V_-')#S!"U]2=$5;H'B^$^]NB_LQ;0')KDT9\_?Y MP>!C=*\-IPS.O7P-UZC<9Q6=YMYK5_'-=A#5ME_\.<%F_]"UCR94_+8%G7@!F!6 MM=0G(5CDE]DUY0F+!^TF?SP33=:V\:X[;UL4!V$*7M?$.[$'VT$X?*/PJGH[ M+<-"*)!'T.C[!#E90ID4BR'AK@Z>^ MU"P8?"R=6#+OT%Q.0$(-!YG.5^N4O5!Z2_FCF CU(_,+RQYI#D,,!F$NSP>Z MO\,+LU]8\6=:W- Y6V;)WVG<:2M3/HA WPY)]:#-V1TY03Z,9B"&K*W^=*S, M>*O4'][PCC+A-(4#6%(PDC4P2&ZR"-%FYD,VU^RMH:NI^X+Q^D\@9]I)"@WB M5V$PK TWA%L)'$ M83UVZ^=_XBPWN1)[^=+AKD9[3;6_%:?\#)H1O;^Z*:Z]W#D:L3C<]^+J,L]+ M&I^5/,F6%7Q9T[SKSIP_4SY/1-6-"Z]1I>"+GWE%'88=_*5;+=3+!Y_5;+"5N4DGC&N&L2"TS1,;VU%M,2+BU2OFS//G=<*E3CMQ[FEV MUG[ID#PT2U/MTD/3? ;7^-E+W>P>&@4]5*;\%8T@5I8+FA0E6*+]#CGMEPYI MR%F::I=#3O.97\V0,]?-/N06E1ZJ0;=-S%'=#.U&4+4RF"TJ5V#7$4ZNKQU$ MW)M?D^TDZ,W^*5R#<&_ULP]$5A9Y$66Q6",=$8A)%4N=:I<1TGS[\4;Q5?4T'I\\)ST'JO<#GEU:/2S53Q%=*NSH/$K)9QKE8HT!G4A^ JW_V=.M M\L_17QD_+86Y7E&>-_Y4^X=!1?Q4@MT[]P3?7D1WR$\^UD> -)_0K$"?S!OY MB0YF3D$D*ZK=*;CW*1P(^(.P'5K/RR:/9R"/0COLHAOZ2+.2$FBHR?OG9"XS M)N4_0+[.VW*]3E].EIQ2:?AUQL%/+Y@!'E.-U@K[*.$PQ2.0 M#JG4J)*BTB4E*)-<:I.H5=\3OV1DEDR4(4: 3%,"'_.FV2CU8&S;HE(MZ4;H MXN#>>,#ZP-PJY4F3K$8ZE&&I>!KE#_!_YP+ 8Y1"3.])%I]27D1)=BDW\F2@ M;UW+V)ND.RHX&'UWVA ML7=2*@[*[[(JP\$ Y1Z1N?A/0C?%R\Q^\^H#)-E\ MH@;2OEHR2C,8V\=5I:6SGQH.OH[" MJN3$$,JP>5)IDZBCWOH,59JY/7'M(LF2_('&GQB+Y-&)KNHCE(,Q;G2%6M)Y:^+@W5BXFG?!I3Y90@'2[LD22"J+$"X#R64A MU2[^'OV"CF>35_@O&'=0ST\OZ*SN6XW>I.U2PL&U$4AU4V[7[\P;?BT8#T$P M<"/6\.%;,=G/A$E-LBC]R-@O,BIVMFA_%T[&#^LECV(E@.$5Y81;@[^BFILU M^1:%X"#H*Y K:_9&5+ SI>28L+HX5N)C!I/Q$_5"CO1!_/&69?#/L3TGQT!P'G3_/TQ+.=&&G2/QO?!<] MZSIIBV)^_C9LAG;*[?WWFBHH1ZUBS"&)2JFK90J=W/P<,JYC"$I#I>FG?P,@ MZ[&;S!V;R56VF-8K'$B(T)STM@FL;^E2NLV&:EOD0U+%";O+':,P&C*Y$)K/ MW>_+/,G@<8"\U@@\8TA_Y#IZF3_0^2_7G!5T+A/S<";\T]5G"C@5/\LA_W/, MYL&Z17RKA(:3HU/G;/F!'?90HT76K1K\$_2^F:*+(#/G%8LR0X_T?\;5 5IL MP_:^S,3Z?E4G5S]X@=6UTUR[JDS6%9F MKU, :4LXFF2PL)48PO#Y"PK7Y\V=993$U4TNF(YQU&J3!:6;-$XT>:0QN7^1 M?0@!\%'V N=4,5T(ISL6ZSJDO2N?!JL:(W=TKTD46_\Z<+HZN%'WZ.!RS:I^ MC>8/B>A4V:-02!VQ(=9HTM<4G4#8?9HLJ[OP!T",-JR[VYK-VY0*-ZS2N.CA M U7'D*Q=1TN&M 1I7ULK'J*"K*(7?X. K<]OZ*+,8@@J]C?Z'CJX^M\?\*B) M0- RB3)HM?A-!4+^ARL",SQ21855/ZN7=:0IZ1XJ.T!B L[D:;L"2XU93&$ MXC .)56V!FXS@F!2>1TF4S,)D3[6.TVP%'>M9"VRN(CC!JIN[-:/;]8=M=EV MZ.[&P9[#Q$O;CU1P"E9H5U>GIFY21)#UC@F?NDZ-X;&G4@RM%]$G>;+,DH58 MBHI>DGLIS&WXC1W0J^0%9/!F\OD^J_ M2FT(F:N?7"7"W(M!"4.TX%&61W*#;Y)NODAX7HC%?!9#4]XQ-BOYYR@O.J;/ MT/O>FKA(,1:V>Z=0EDC:(HDHDXA"257J9OZ>=./V)(O%7'5#'UGZ2/E%-)?O MI#BVUAI"1]IP.4 M'XEIMM[>K^Z:5.[;/>-<^E6B0+#RD.D/O"R2K^E:$B;IE"_T:ZC9D#KPB0Y#%O576K_GOOF.\)&J#\'FY;K]E#S$5;,13#.MJFWR MN4R+9)WZ$6FD/BZN; =>M[>YJM4,74NBQRA)Y;^J0Y'6B^[O:J=]9DT[7< E MQLLL+[AL1#&6:'7G\;U" J,DKNYVP52NT@D)\M4ZXE]W]JYCN-J9M*602*R1 MDI7L->$BE["'/$UO);FDW2SK>.[@K:N]99)$UEL.F/8CAKC6)O*1LLU2)IMJ M_7)%HYS"$TKYA=S4U,S)0PE<_6&"I^Q%M'U0[=Y2DH*F?"HN[[S:!.=[*03S M4WEGL!&J@O^GZZ*K)+J7TWESKGE#5U$"B0)FBPM!JBC],XW4I M'2W=2N!LZ2$\8TL73VS:EH9%LJNM-S)(6UL!:&YO$)VTQ6%1ZFCPC0C.]E;P M&9L;5LB3M/:N7^9 U0]^8(W1)'GGLE,O/KXI8)(>VU\J?U1]-P*Q,:4_^$7% M$TT?*5FQ3"PUZV?/J'Q=25XSDD&Q*Y87\H0_*](7LBZ%9R73KOZMC+CPO<7? MJN,OR$0D$-=),OO'_=W,T]-%O@=*O(^**>.!FY=0D@U))D-_8.=:1DMW+K+6 M2?K59..3=3GF9/6H:+++*NGB%>P/-U3W&F%CK>67H%45W!\52QW.V6HL% M\X1V+*!6<%:#8DZ0 ^--SGMQ#C&0[ MU:X$N3A08Y7)UN!ZE,+[4T:<6GN4TJA'(J9$S71ON_XVIQ M/3@E:78C-55^R%7$7V8+N7:20RU*P2VY$.Y Y_KC#84C_OB.R2.Q_ YN5-S1 MY^)CJO/$=E(JLL[<8964!6ET7Z81;Y)UE%R:U[SSHF(R2)Y"-!&*8922Z<#W:U,]^#'I]FZ] %@:L'6U-EA6U)GLHM/^7K-#U?^C,&__JMVOX#)ZV G7J M=I@G2B5S/7TBC5Z5HJ75)#]5NO\SU>/D$S5C$W0E)BX+854I1,UK :?>:V]%I^9O!\H7(>W5]AM! MG,VOP6?M@8W\1)T@-WX?6!I3GL.>3#]LTBSU\V_1-+\%G+("[HC^AE3"Y*00 MCLU]6317]Z\C'(-"..E^O>/2P3E4[% MHT:N*2KQB3KI$V=Y?LW9(M':J\[/ MB)I>AVK8RE*&5$(3M6V[+KW,YFQ%KP0@71MKQ!"UM0W=L,U;65()DZ] _.N) MFG\#N'FG+\E* :Y&R;+\(UTP3BNYN^B9YN?/!8\8C\6*G[]<%G0E9T&XY,_2 M5+:!>MTBP.<0T2%$+=6$1')D$FM MSS@40K#=XL:F>(Q2\HAT9*=R.J(D@\$\R\Z27+Y15#T^)=?.[[5^B%4#T9#P M!*IX*Q!O4ALXEI&.+NQ 3[JI<%D%5M$S6OW_R\R>9VV,'J*.&P578]BD$OFJ M4?\:SN2;$LBF"#2=V 3W)?J7=:T*J+M-A].SOSJJ:/KI&O)])G'S!'@];\*I M%[Q$8-XXW:XDU#T[J@*>75Z7V?HCL""7Q6$UNM?5ZS/C+&ZMA+IW35C'VMI: M'U/'\9+&G5T?[[X;Z&'O/A-<_QZ$$DBG"#2=*$W"9H>[L@W"\G3WRZEI%;=5 M6:@[>V05/ E0V=U-L;4)EC:Y?]1 IUJ^BR]#^-(U9X])3../+S_DD+VBW?@Z MF1?)HW&0^VLCZOTM0*O'^P6!,DA3""33_ K*$=W^-=EL&V[*FJA_FS1!=^QD M+F\8",00\O-R+2H$L>#:>.;QVHCZ=PO0FF?MJUL2!2-U(:0IY8C(\6H$<.W[:HZ8=O'1,HXP#;N#'=4Z9>"HAZT0^GDA&\ MCER4:F(@MK%PC>9$W61\ $/7149A1-WCQJC)P-!YQ>.J><6CTD+0+75$]C4\ M= B!E*Z>&/X\?X!G]VX$E<\7"SK7#NJP M"!#Q;****_F2Y,5DR=9.^4=D\^GJ1W"GAW_K*520B&:M?41:8*1!1@ :J; = M(O=W3F5$1[R[J<>>B#;9%EV=/D+&>>DWWKH2B R- 9BZ25:+'1$I.'5#PUWG M^K)>3OFC:1O;)(VQ \P@C9U!6AW2*!W*\SS3&S0',"6<$/:#KUBV+"A?Z?:8 MIX[KE%6I3PYUHT$KB&@@V/&9HSOK_81:8:KP\H9'NI9O?T34VBHF)3*\:E>0 MF:Q1(0MSGQ>Z'/KZ-O?31=4E(R&K/08%'!%E;+2E'-5I/:ZC),;8J3]T$JF? MRS3IZOWA5Q5T*-WMQ+]-WW<+)56II"H6P0[Y^+?CMB\%$0M> =ZQP:X=]+"B MZCP65Y5*H%B,%!#&[@M]+NYD2MG/D%'6>6[B4\:A=+\-^G:=#QU-9ME47I*K MMIKW_T:J'E#7#A&_HD=%,9A[=/BDWVCE0^O5'N;7]"L4A+AGAP_UC=4]L'[M M07Y%MT(Y2'OU!-+[Z5[@VZJ ^I?/>[M.KG*D5AUM2@-:5=OT[L'U*%;]&&M M?42$.J9.&[,J'E4 ]NXQ1[SXWNH>F?M=O?F_68SCI&0M9N M"F]ZK8W=ZVPKS*;<5O!X;'6;]^51]Z &I[;;+(KX>FG;9^ /HJ=Z2,?UU00K M0G>%MGRP_1#ZJ@?4])Q<#CLP4^6&]*C#=J^I'T3W=(&:NV>64;S=LX.WS@^A MJS1PE22Y=0I><@+7<[("/(Q.8F[RT\E]7O!H7N#IQ%%/DV/NIBX^3Z]O@G7R M!O]6;XYCZ@ 3-GWCU])398S2\,9!>U1MK:)R4%S3O-T_78E_B3\W?Q+_ <]U MB;_\?U!+ P04 " #RA7!1^-A%-SPO #O_P( %0 &YA;G@M,C R,# Y M,S!?<')E+GAM;.U]ZW/<.)+G]XNX_Z'.$[';]V]&)/)90*/Y7]]\O3D8WYRRF+ M_SSZQ0LS\1-V1D,2CT[8_D"A@\=?K\W6W MBS1=?7KW[N'AX6W$[KT'%G]/WOH,UMT-RV*?K/NZ^O3[24A)E":_7WH16RV\ MA(QNB;^(6,CFE"2__]=='/Y^]/[H_?N/'][_'GG1XS?QIZ/W;Q]G7-2)E_)N MQ.__]]'D\%#\Z\?;H_>??CC\]/ZG_P_D*?72+%GS]/[Q??F_@OPO(8V^?Q+_ MNA/<<0"CY--C0O_ZIJ:)AP]O63Q_Q]D\?/=?7RYN_ 59>@NB.H;']Y5[*Q[YK^EBO8U3A+Z*'3PX?#M8Q*\J92?:S!F(;DFLY'X+[>G]5>C"GAN1,MW MXK?O3A@?(IS5G&X1DQD?!1SY@\H.1.=_V&B4/JWX4$FHL/0WHW?]/QPE+*0! MMZK@V N%QFX6A*3)U\C+ LI_6F_!_QR0*"&!GM6MNG4KW)47\P&Z("GUO="2 MI)W?L""V&.ID*?S-=#9="7_)[7] <+?IW[*X-RGSOR]8&/ YX/0?&4V?[(C= M]SN6Q3_QDL59R!XL@6W8_4#"'GL)Y1^_BDG"V @F0@ICXSOICA$OLD MCBXHMP"NCB<=6TJB@1B;D,2/Z4J(/)T=9PF-2)+H&%,2#<38-;DG44:TO#3; M#?3Y4R^.N/:3*Q+?++@CUK$A:S\0.V>4_]"G7GC.URQQE@\P'4LJFH'8NF0I M2<91<,$M@(_WF' +U;&EHAF(K?.(VP1?]5.]^70T'8B)"\+_JOW^9JN!/IU; MX(%8? 9BG\.]+,@-:LB&8H[.(SKC:YHH/76@T3#8) M!ATL,%ZZVMH=.#"^0,1NK!$FP%:=VEPH34CJT3"Y]&*Q>;C73L9&G0R\7C'E M54=G:3UCRB:4WN+"PI1EDSZ&]ZOEEPP<:X-B2,\*9*:KK04V#DWX.+3(R)$) M(T<6&0';M)+([B0(M"$8]4Y8!6O5L)L=+H2-)=FB3S=+$Z!9;=>K4]' X W4 MO4K852W$Q>?%[QLDY#$E4? 'H0!PIY4$'_L>B9TE 6G42#2)M16 MVV@*U/.?7)IOIW0.G;'(OKG,EG?/"X!$@H@ #\[7 XJ977JEU(B..<;56X6 M7LFGVB%U4P!!^.C2$ZED=0C"S=(+PV;"1I?N&PW!VR!W.N\4S?%")S[A#G#. M8N6>L]$0JFJ'6\Y.T1RJ^G1)XCGW=9]C]I N1 37BY0JEQ! 5>]D/PH0U:5C M69 P!&A^LQU4X4YVJG+!7"YEV'(I%K?,_YX?6B33+,WO17";4"YHE'10')SL M9.&".PTC% O?8KM]QG\FF5X5S:$H.-GI:L5$H'RQZP"KOM88JG@G>UN-B!UJ M_\N[EA07_ W-Z,_KC\PJG]AM/[$O_<^8E=SFJ67(P][Q588XD3)/J)TV[ M+'_\;2W$=+;.Q+UB":4%!:S9V==JDUW 6#1%0<:(B++R+K@O]'W/:Y]T*1>S].3[PX M?N(+EOQ2I1P=(+FSTS,0$*R/2)A '/N^"!\GU\0GG.&[D%R25!ZVJI2BI')V M,M<#,HC\.)"J4P9R]E MJ1?F+1V/.K8B_?,EBWR='Y0T=W8>:82*2E0< M:!31YMO4ES+E7%#OCH8TI?F-JG8Y"WW( =Z#NQ/0[6-$IGK",?)J M7(-#2"H:=P>I?6&0HH@ZSG0ADAVJJXW:97QW:W=GL'!E-]&12XT#ETE&;MDU M"<5AQ)47UT23HZ.B<7<^VQ)I=42"H>U M.$LO']WTL>]GRRR/"_#]"O6I8@:"T$)ALQ8H,88-KA$<"+8%-%DSP!&R M%@T98'7P4I;PNF43:,,FH83BC#5\ M7-H#:P+W4*NM]AW"A:\&'0H@6C/VY\ M\K6(@;TE5!BR!V$'9RR>L.PNG65A^]ZK_FS?K)L]+H'01U\XIO+-K14?8-,X M5T20K^R;S_;I=IAR>M;SG5QA<%@ ME*D$+WSG29*90E?1N"ZP,#!LFZK "YFZ"IU"P#YEZ"QN9P<%SU*%ND&#>.;S M((C8==6&+9 T4 XZ-.'3GY+(=8&'8=##/?&U&-7->E("UY4;AD0+XWQG6')5 M)EJ?F<[:4?^0F,&F.:?!GK6XR716IECRW_:I3ODG5:#GYI;_Y\OIY>W-:'HV MFEZ=7H]OSWD#W'4JQ;,92[(62A_5D1(X#=27W.2/$@,B4F4[W4!LV;.5X:B! MH!6BWY2A7N\" P1\Z))S_D=%9DQ76QQ0=!N2#($:^_5+.L.AD,1I#0'^MZ;V M^8]$/:@@\U.^5B7Q/?7)^)%VZ9XW[6ZY#YJ7,E^+I[E1>WYB4G"43-C2HY%2 M]UW-'0,@U:T,@BX9GH/6;BNC"?Z^$,D#8^O=^D8S9[M5M48E@88."7$LE$O6 MGB7)<^F!6$BHG&UN^D.CE!\'4F66/*!Z=[LEEL.KUBJCE6K2+2,J!,ZX>")U M5C#X*TT7U9O=IX]^F(D=E4B&Y_\$M]ZC%B2SSER?4TGQZ82QCZ)P(+V^TE>6 MA04,.@4)FF,IW?#3BHT#G1.6I-/99\:"NIN_8:$R$B>G<7W^I%=[,YJCDQ\' M3I]CEB1\@IVI=K8:N3YI,091(BF-, M/1M6M1^A4<9E>SY3.B8S%I.B'=^*D.3TD4O+E4PC+W[*%\SBUR<_.PCL#^^XI2]%*EQWS64BZ;I03."ZWWLPZIZ.;(?BR0CZQ_:2I)#IO-$,3T%U7=2@4[Y]'Y#59;S82Z@O!T_2W'E-=3"(2GEQ M3.2_$O$L"0G&]]S!S,EE)F+TTUDKH44#E6$WSDNM@R'LI1\%XS]K#DC>T\8Z\_"H4IG;#EBD7"=TK2^)H2=9/M(S;=DEA)\#-?5F[R M)DWTJU9DWBOW9;1 =+ M1U,TV2X&F$@EQ@&(I'"6#AP-F>NTESY @32! [1FV2P=6K+VKG-B^L"DEAT' M/N>1'XN"_1-2_/<\:F\1KED8GK'XP8L5L2CCCM#,6KK(1D\5X(A4J*2^:3+.;B7>7< MY=4=\M]-5WD2P>DCB7V:J(X->G3E>OH=T WTT2$B7]YFOS#\86Q V9?K]%6K M1@#0(@XK& =_SY*B>OTMD^P$54[TD#_EOE,%@$+GKC%[[$U!+5ZCA+=QE M?WQ;]*ZS?7X> OATAR,*U%042P@T2)#B-$*18 M;Q,%,H$9>["O2S9+**/)53OQDL59R!YZE8;[$9ZB=C*^^=OH[&+Z*_+2<+6< MI[5JC#+1.JCL&'ZA]+ MB14%ZNV)>T#-XICQ+:_$+($W,!(VK^?P9?@=2XC[*7]C)R'B1)%/0[(A["T# M:E7O)>Q\S?41HU6[LPD0#FAV=ZS/''8(.4^'^ M7P*N+E5NGGIHMJD=[5V?1.[0--0JP^$!ZKYI798]FHL*7:(V%[?IXITMQ8GH7\5DY5'Q>'8N M3EGWAL]K>>WI8NEK8A:P_A >-VYM,"::?(F65'G-*^^I[[RR)D5XU#G8K-+0 MS_Y'/SM%C3,NQO.CX(;6T*)&>"@ZA$%(M/02;:+RBV4]=A.#:)$ZKX-DP1HD M^L&ZD<@G-5$'L7BJNYC>^&17LV:^)3/:6P)[=%Y5R0+X9MK<_]4#?+<^Q&$Y M@@).MD]5#;6Y[Q41)1*+/5MB,1'#N'^HW>WB)=PM4S%ZZA;'_,77W%6>K_^/ MC,:$2\=93I^N0B\2#RZ)K+:\K+[<)DSZ@.*^ZW!H7Q!9;TV\\!FK0Z%#>!6X M!5F+JUJU('-MOM 9:WV<9&G&,NX?:G?60KG#S5@]=8MCQBJ8)Q=B?W 54R[' M2EQ-*1ROW PT9. DKQU[E;Y0,1/A7\I4Q)7G$Q+D#QAW$\7*YGI M+ \,7[!H?DOB)7SX*SN 6LNN@Z'#>P* 'G$XA6ZF:Y5 36'?((4";BT*Z0#P M#MWA@SIG3P3-%#LZ67LHJ+L.,0X/:EM+.)"$*V"(L T<\5V'!(=!W%R;^QX2 M%.**_XMH^;T7DCSCE.N(^N*N./_%. HV?U!K652T:9\DEZ_9GS[Z"R^:DVN^ MN#F=S8@J=+AK/J!VC"G$Z :K?VD+MV2P!M<87XK];6U.J$JP8C0J@[HM'^R7 MTMZ16;VPLCW9:A7FZO/"2GWGT8S%RP)!?=42: =00['_*@7<4 RU@V.!7CW, M+"JZ:9(1&PVA$-E[C\)0W]UOH#<$QX%*)8Y(=^1_?#[SCX*.Q;ZX7AFR)(N) M?@1NWS,4=_L/7)CY\"'TB<4Z\@S:_/9,0$5YQ>2\2(L-CK/TDJ6_D=RL558 M[0&*MK5 Z�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end